register_number stringlengths 11 11 | secondary_id listlengths 1 10 | url stringlengths 44 44 | brief_title stringlengths 20 290 | brief_summary stringlengths 63 5.05k | official_title stringlengths 25 483 ⌀ | intervention listlengths 1 19 | arm_intervention listlengths 1 21 ⌀ | f_condition listlengths 1 135 | sponsor listlengths 1 1 | collaborator listlengths 1 25 | experimental_drug listlengths 1 13 | study_identifier listlengths 1 7 ⌀ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
NCT02686697 | [
{
"id_field": "org_study_id",
"id_value": [
"GCO 14-1119"
]
},
{
"id_field": "acronym",
"id_value": [
"CACTIS"
]
}
] | https://clinicaltrials.gov/study/NCT02686697 | Carnosine and Cognitive Training in Schizophrenia | This is a double-blind placebo-controlled trial to evaluate the effects of the combination of a cognition enhancing drug, i.e carnosine, with cognitive training in patients with schizophrenia. All participants will receive the same cognitive training sessions and will be randomised to either carnosine or placebo for th... | A Double-blind, Placebo-controlled Study on the Effects of Combined L-Carnosine and Cognitive Training on Cognition in Schizophrenia | [
{
"name": "L-Carnosine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Carnosine"
],
"type": "Drug"
},
{
"name": "Placebo",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Cognitive Training for 2 ... | [
{
"design_group_description": "oral doses of 2000mg for 4 weeks total - 2 weeks medication phase only, and then 2 weeks combined treatment with cognitive training.",
"design_group_title": "L-Carnosine",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22... | [
"Schizophrenia"
] | [
"Icahn School of Medicine at Mount Sinai"
] | [
"The Stanley Medical Research Institute"
] | [
[
{
"name": "L-carnosine",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "CACTIS"
}
] |
NCT00169104 | [
{
"id_field": "org_study_id",
"id_value": [
"D-0140"
]
}
] | https://clinicaltrials.gov/study/NCT00169104 | Effects of Granulocyte Colony-stimulating Factor (G-CSF), Trastuzumab, and Vinorelbine on Immune Cell Function | Trastuzumab or Herceptin is an antibody directed against Her-2. Her-2 is a growth factor receptor which is present on the tumors of 25% of patients with breast cancer. The addition of trastuzumab to chemotherapy has been shown in a randomized clinical trial to increase the response rate to chemotherapy, the duration of... | A Phase II Trial of Trastuzumab, Neupogen, and Vinorelbine Investigating the Effects on Immune Function and Clinical Outcomes in Patients With Metastatic Breast Cancer Overexpressing Her-2/Neu | [
{
"description": "5 mcgm/kg daily Monday through Friday weeks 3-14",
"name": "G-CSF",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Neupogen"
],
"type": "Drug"
},
{
"description": "4 mcgm/kg intravenously (IV) over 90 minutes week 1, then 2 mg/kg IV ov... | [
{
"design_group_description": "Subjects will receive ten doses of G-CSF at a dose of 5 mcgm/kg daily Monday through Friday for the first two weeks of the trial. All patients will also receive trastuzumab at 4 mg/kg week 1, and 2 mg/kg week 2 during the first two weeks of the trial. All patients will then receiv... | [
"Metastatic Breast Cancer"
] | [
"Dartmouth-Hitchcock Medical Center"
] | [
"Amgen, Inc."
] | [
[
{
"name": "曲妥珠单抗",
"lang": "CN"
},
{
"name": "Trastuzumab",
"lang": "EN"
},
{
"name": "トラスツズマブ（遺伝子組換え）",
"lang": "JP"
}
],
[
{
"name": "非格司亭 （安进）",
"lang": "CN"
},
{
"name": "Filgrastim (Amgen)",
"lang": "EN"
}... | null |
NCT00111956 | [
{
"id_field": "org_study_id",
"id_value": [
"TNF-alpha (completed)"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"F32DK068902"
]
}
] | https://clinicaltrials.gov/study/NCT00111956 | Effects of Tumor Necrosis Factor (TNF)-Alpha Antagonism in Patients With Metabolic Syndrome | Metabolic syndrome is associated with increased inflammatory cytokines and reduced adiponectin, that may be mediated in part by TNF production from abdominal fat. We reasoned that an anti-TNF agent would reduce C-reactive protein (CRP) and increase adiponectin, improving the inflammatory milieu associated with metaboli... | Effects of Tumor Necrosis Factor (TNF)-Alpha Antagonism in Patients With Metabolic Syndrome | [
{
"name": "Etanercept",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"name": "Placebo",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_title": "Etanercept",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_name": "Etanercept",
"intervention_type": "Drug",
"normalized_intervention_type": "3d1aa88... | [
"Metabolic Syndrome X"
] | [
"National Institute of Diabetes & Digestive & Kidney Diseases"
] | [
"The General Hospital Corp."
] | [
[
{
"name": "依那西普",
"lang": "CN"
},
{
"name": "Etanercept",
"lang": "EN"
},
{
"name": "エタネルセプト（遺伝子組換え）",
"lang": "JP"
}
]
] | null |
NCT03624530 | [
{
"id_field": "org_study_id",
"id_value": [
"TKI post-HSCT- MRD+Ph+ALL-2018"
]
}
] | https://clinicaltrials.gov/study/NCT03624530 | Effect of Prophylactic TKI Therapy Post-transplants on Ph+ ALL Undergoing Allo-HSCT With MRD Positive Pre-transplants | Allogeneic hematopoietic stem cell transplantation (allo-HSCT) in early first complete remission improves the long-term outcomes for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Relapse remains a major cause of treatment failure even after allo-HSCT. The prevention of relapse is essential fo... | Effect of Prophylactic Tyrosine Kinase Inhibitor Therapy Post-transplants on Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia Undergoing Allo-HSCT With Minimal Residual Disease Positive Pre-transplants | [
{
"description": "TKI was selected according to the mutation results of ABL kinase region. Imatinib was initiated at a dose of 200mg/d, dasatinib at a dose of 50mg/d, and ponatinib at a dose of 30mg/d. Then increase the dosage of TKI gradually and increase to therapeutic dose within one month. The duration of T... | [
{
"design_group_description": "Treatment with prophylactic TKI will be initiated from day +30 to +60 post-transplants. TKI was selected according to the mutation results of ABL kinase region.",
"design_group_title": "Prophylactic TKI Therapy",
"design_group_type": "Experimental",
"design_group_type_... | [
"Philadelphia Chromosome Positive Acute Lymphocytic Leukemia",
"Tyrosine Kinase Inhibitor",
"Minimal Residual Disease",
"Allogeneic Hematopoietic Stem Cell Transplantation"
] | [
"Nanfang Hospital"
] | [
"Guangzhou First People's Hospital",
null,
"Sun Yat-Sen Memorial Hospital",
"The Third Affiliated Hospital, Sun Yat-Sen University",
"Peking University People's Hospital"
] | [
[
{
"name": "达沙替尼",
"lang": "CN"
},
{
"name": "Dasatinib",
"lang": "EN"
},
{
"name": "ダサチニブ水和物",
"lang": "JP"
}
],
[
{
"name": "甲磺酸伊马替尼",
"lang": "CN"
},
{
"name": "Imatinib mesylate",
"lang": "EN"
},
{
... | null |
NCT02684812 | [
{
"id_field": "org_study_id",
"id_value": [
"2012-000343-26"
]
},
{
"id_field": "acronym",
"id_value": [
"ULTRA"
]
}
] | https://clinicaltrials.gov/study/NCT02684812 | Ultra-early Tranexamic Acid After Subarachnoid Hemorrhage. | This is a multicenter, prospective, randomized, open-label trial with blinded endpoint (PROBE) assessment. Adult patients with the diagnosis of non-traumatic SAH, as proven by computed tomography (CT) within 24 hours after the onset of headache, will be randomly assigned to the treatment group or the control group. Pat... | Ultra-early Tranexamic Acid After Subarachnoid Hemorrhage. A Prospective, Randomized, Multicenter Study. | [
{
"description": "Treatment until aneurysm treatment or maximum dosage of 4 gram",
"name": "Tranexamic Acid",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Cyklokapron"
],
"type": "Drug"
}
] | [
{
"design_group_description": "Eligible subjects are randomly assigned to immediate administration of TXA (1 g i.v.) after a diagnosis of SAH, as confirmed by CT-scan of the brain, continued by continuous infusion of 1 g per 8 hours to a maximum of 24 hours after start of medication. A maximum of 4 g TXA (1 g b... | [
"Subarachnoid Hemorrhage"
] | [
"Academic Medical Center University of Amsterdam"
] | [
"Fonds NutsOhra"
] | [
[
{
"name": "氨甲环酸",
"lang": "CN"
},
{
"name": "Tranexamic Acid",
"lang": "EN"
},
{
"name": "トラネキサム酸",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"code": "25d348828a9828a289325023e5d55e59",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "aa82085ae32eee5a2825aa95545235d0",
"s... |
NCT03457324 | [
{
"id_field": "org_study_id",
"id_value": [
"ITS-148-14FP"
]
}
] | https://clinicaltrials.gov/study/NCT03457324 | Efficacy and Safety of Chinese Medicine JCM-16021 for Diarrhea-predominant Irritable Bowel Syndrome | This is a multicenter, randomized, double-blind, placebo controlled clinical trial, in order to evaluate the efficacy and safety of Chinese Medicine JCM-16021 for diarrhea-predominant irritable bowel syndrome. All patients will be evaluated for study eligibility at Visits 1 (baseline) and 2 (2 weeks). On visit 2, patie... | Efficacy and Safety of Chinese Medicine JCM-16021 for Diarrhea-predominant Irritable Bowel Syndrome: a Multicenter, Randomized, Double-blind, Placebo Controlled Clinical Trial | [
{
"description": "This prescription with seven ingredients.",
"name": "JCM-16021",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
},
{
"description": "Placebo",
"name": "Placebo",
"normalized_type": "3d1aa88261d64c038413723... | [
{
"design_group_description": "JCM-16021 granules 8g/sachet, three times daily for 8 weeks.",
"design_group_title": "JCM-16021 Group",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_descr... | [
"Irritable Bowel Syndrome"
] | [
"Hong Kong Baptist University"
] | [
"The Chinese University of Hong Kong"
] | [
[
{
"name": "JCM-16021",
"lang": "EN"
}
]
] | null |
NCT01720030 | [
{
"id_field": "org_study_id",
"id_value": [
"Levosimendan in AKI Study"
]
},
{
"id_field": "acronym",
"id_value": [
"LAKIS"
]
}
] | https://clinicaltrials.gov/study/NCT01720030 | Levosimendan in Acute Kidney Injury Study | We hypothesise that levosimendan will have a positive influence on renal function during acute kidney injury in adult intensive care patients. | Prospective, Randomized, Monocenter, Double Blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Levosimendan in Intensive Care Patients With Acute Kidney Injury | [
{
"description": "Verum therapy",
"name": "Levosimendan",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Simdax (R)"
],
"type": "Drug"
},
{
"description": "Placebo therapy to safeguard blinding",
"name": "Conventional therapy",
"normalized_type"... | [
{
"design_group_description": "Standard of care as protocolized locally",
"design_group_title": "Conventional therapy",
"design_group_type": "Placebo Comparator",
"design_group_type_normalized_id": "20d1ebb7d90a3d9b81daa54f73163ecb",
"intervention": [
{
"intervention_description": ... | [
"Acute Kidney Injury"
] | [
"Viecuri Medisch Centrum"
] | [
"Orion Oyj"
] | [
[
{
"name": "左西孟旦",
"lang": "CN"
},
{
"name": "Levosimendan",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "LAKIS"
}
] |
NCT05277896 | [
{
"id_field": "org_study_id",
"id_value": [
"210500"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"K23HL153584"
]
},
{
"id_domain": "Patient-Centered Outcomes Research Institute",
"id_field": "secondary_id",
"id_ty... | https://clinicaltrials.gov/study/NCT05277896 | Randomized Trial of Sedative Choice for Intubation | Among critically ill adults undergoing emergency tracheal intubation, one in five experience hypotension, cardiac arrest, or death. The sedatives used to rapidly induce anesthesia for emergency tracheal intubation have been hypothesized to effect cardiovascular complications and patient outcomes, but the optimal sedati... | The Randomized Trial of Sedative Choice for Intubation | [
{
"description": "Intravenous ketamine as the sedative for induction of anesthesia during emergency tracheal intubation",
"name": "Ketamine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Intravenous etomidate as the sedative for induction of anes... | [
{
"design_group_description": "Patients in the ketamine group will be assigned to receive intravenous ketamine for induction of anesthesia during tracheal intubation. A dose of 2 mg/kg will be recommended, and the group assignment sheet will contain a nomogram providing the recommended dose for a range of patie... | [
"Acute Respiratory Failure"
] | [
"Vanderbilt University Medical Center"
] | [
"National Heart, Lung & Blood Institute",
"Patient-Centered Outcomes Research Institute"
] | [
[
{
"name": "依托咪酯",
"lang": "CN"
},
{
"name": "Etomidate",
"lang": "EN"
}
],
[
{
"name": "盐酸氯胺酮",
"lang": "CN"
},
{
"name": "Ketamine Hydrochloride",
"lang": "EN"
},
{
"name": "ケタミン塩酸塩",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "89d4a2e9444aee3e2a2a02588a928854",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code": "a550eee3532e5a2e32e82280a2a94da8",
"s... |
NCT00374205 | [
{
"id_field": "org_study_id",
"id_value": [
"01KA22062006"
]
}
] | https://clinicaltrials.gov/study/NCT00374205 | Randomized Trial on Effectiveness of ACTs in Ghana | The purpose of this study is to compare the effectiveness and safety of two Artemisinin Combination Therapies (ACTs) for the treatment of children with uncomplicated Plasmodium falciparum malaria | A Comparative Assessment of the Effectiveness of Artemether Plus Lumefantrine Versus Artesunate Plus Amodiaquine for the Treatment of Children With Uncomplicated Plasmodium Falciparum Malaria | [
{
"description": "Artesunate 50 mg and Amodiaquine 153 mg co-blister tablets: 3 days once daily weight-adjusted dosing according to manufacturer",
"name": "Artesunate plus Amodiaquine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Arsucam®"
],
"type": "Drug"
... | [
{
"design_group_description": "Artemether plus Lumefantrine 6 dose 3 days treatment",
"design_group_title": "AL",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Artemether ... | [
"Malaria, Falciparum"
] | [
"Bernhard-Nocht-Institut für Tropenmedizin"
] | [
"Presbyterian Health Services",
"School of Medical Sciences Kumasi (SMS/KNUST)"
] | [
[
{
"name": "复方蒿甲醚",
"lang": "CN"
},
{
"name": "Artemether/Lumefantrine",
"lang": "EN"
},
{
"name": "アルテメテル/ルメファントリン",
"lang": "JP"
}
]
] | null |
NCT03608163 | [
{
"id_field": "org_study_id",
"id_value": [
"2018-9208"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"R01DK079974"
]
}
] | https://clinicaltrials.gov/study/NCT03608163 | Novel Approach for the Prevention of Hypoglycemia Associated Autonomic Failure (HAAF) | The overall goal of this study is to develop a new and practical way to prevent the development of Hypoglycemia Associated Autonomic Failure (HAAF), which is unawareness of hypoglycemia (low blood sugar) in individuals with diabetes. Previous studies suggest that two medications, naloxone and diazoxide, may increase th... | Novel Approach for the Prevention of Hypoglycemia Associated Autonomic Failure (HAAF) | [
{
"description": "Naloxone Nasal Spray",
"name": "Naloxone",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"NARCAN Nasal Spray"
],
"type": "Drug"
},
{
"description": "Diazoxide (oral)",
"name": "Diazoxide",
"normalized_type": "3d1aa88261d64c0384... | [
{
"design_group_description": "Susceptibility to HAAF evaluation: No intervention medication will be given during episodes of hypoglycemia.",
"design_group_title": "No intervention (Susceptibility to HAAF evaluation)",
"design_group_type": "No Intervention"
},
{
"design_group_description": "Nalo... | [
"Diabetes Mellitus, Type 1",
"Hypoglycemia",
"Hypoglycemia Unawareness"
] | [
"Albert Einstein College of Medicine, Inc."
] | [
"National Institute of Diabetes & Digestive & Kidney Diseases"
] | [
[
{
"name": "二氮嗪",
"lang": "CN"
},
{
"name": "Diazoxide",
"lang": "EN"
},
{
"name": "ジアゾキシド",
"lang": "JP"
}
],
[
{
"name": "盐酸纳洛酮",
"lang": "CN"
},
{
"name": "Naloxone hydrochloride",
"lang": "EN"
},
{
... | null |
NCT01938781 | [
{
"id_field": "org_study_id",
"id_value": [
"2013ZX10002004-1"
]
}
] | https://clinicaltrials.gov/study/NCT01938781 | Optimized Treatment and Regression of HBV-induced Liver Fibrosis | Patients with chronic hepatitis B histologically confirmed of liver fibrosis S2/S3 (similar to metavir F2/F3, Ishak 2/3/4) are randomly assigned in a 1:1 ratio. One arm is entecavir alone for 2 years; the other is entecavir alone for the first 0.5 year, entecavir plus pegylated interferon (peg-IFN) for 1 year, entecavi... | Optimized Treatment and Regression of HBV-induced Liver Fibrosis | [
{
"description": "antiviral therapy",
"name": "entecavir",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"entecavir dispersible tablets"
],
"type": "Drug"
},
{
"description": "antiviral and antifibrosis therapy",
"name": "Peg-IFN",
"normalized_t... | [
{
"design_group_description": "entecavir, 0.5mg, qd, oral, for 2 years.",
"design_group_title": "Entecavir monotherapy",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"intervention_description": ... | [
"Liver Fibrosis"
] | [
"Beijing Friendship Hospital"
] | [
"Shanghai Public Health Clinical Center",
"Zhongshan Hospital Fudan University",
"Beijing Tiantan Hospital",
"Peking University",
"Nanfang Hospital",
"Shanghai Renji Hospital Management Co., Ltd.",
"Peking Union Medical College Hospital",
"Sir Run Run Shaw Hospital",
"Tangdu Hospital",
"Shanxi Med... | [
[
{
"name": "恩替卡韦",
"lang": "CN"
},
{
"name": "Entecavir",
"lang": "EN"
},
{
"name": "エンテカビル水和物",
"lang": "JP"
}
]
] | null |
NCT03581409 | [
{
"id_field": "org_study_id",
"id_value": [
"B-1712/439-001"
]
}
] | https://clinicaltrials.gov/study/NCT03581409 | Comparison of Two Different Antiplatelet Preparations for an Unruptured Intracranial Aneurysm | Perform a randomized comparison study of dual-antiplatelet (aspirin, prasugrel) and triple-antiplatelet (aspirin, clopidogrel, and cilostazol) preparation using P2Y12 assay in patients with high on-treatment platelet reactivity undergoing stent-assisted coil embolization for an unruptured intracranial aneurysm | Comparison of Dual-Antiplatelet and Triple-Antiplatelet Preparation Using P2Y12 Assay in Patients With High On-Treatment Platelet Reactivity Undergoing Stent-Assisted Coil Embolization for An Unruptured Intracranial Aneurysm | [
{
"description": "Aspirin protect tablet",
"name": "Aspirin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Aspirin protect"
],
"type": "Drug"
},
{
"description": "Prasugrel tablet",
"name": "Prasugrel",
"normalized_type": "3d1aa88261d64c038413... | [
{
"design_group_description": "Patients with unruptured aneurysms received dual antiplatelet agents (100 mg of aspirin and 75 mg of clopidogrel) for at least five days before embolization. One day prior to coil embolization, P2Y12 reaction units were measured using VerifyNow. Patients with clopidogrel resistanc... | [
"Aneurysm, Cerebral",
"Endovascular Procedures"
] | [
"Seoul National University Hospital"
] | [
"Seoul National University Bundang Hospital"
] | [
[
{
"name": "硫酸氢氯吡格雷",
"lang": "CN"
},
{
"name": "Clopidogrel Bisulfate",
"lang": "EN"
},
{
"name": "クロピドグレル硫酸塩",
"lang": "JP"
}
],
[
{
"name": "盐酸普拉格雷",
"lang": "CN"
},
{
"name": "Prasugrel Hydrochloride",
"lang": "... | null |
NCT02765399 | [
{
"id_field": "org_study_id",
"id_value": [
"LIRA"
]
}
] | https://clinicaltrials.gov/study/NCT02765399 | The Effect of Liraglutide Treatment on Postprandial Chylomicron and VLDL Kinetics, Liver Fat and de Novo Lipogenesis | This study aims to evaluate the mechanisms underlying the effect of incretin therapy on lipoprotein metabolism in subjects with type 2 diabetes and to study the effect of liraglutide on hepatic de novo lipogenesis. | The Effect of Liraglutide Treatment on Postprandial Chylomicron and VLDL Kinetics, Liver Fat and de Novo Lipogenesis - a Single-center Randomized Controlled Study | [
{
"name": "Liraglutide",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Victoza"
],
"type": "Drug"
},
{
"name": "Placebo",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "Liraglutide subcutaneous injection once daily with following dose escalation:<br/>liraglutide 0.6 mg once daily for one week; liraglutide 1.2 mg once daily for one week and thereafter liraglutide 1.8 mg once daily for 3.5 months.",
"design_group_title": "Liraglutide",
"des... | [
"Type 2 Diabetes"
] | [
"Helsinki University Central Hospital"
] | [
"University of Gothenburg"
] | [
[
{
"name": "利拉鲁肽",
"lang": "CN"
},
{
"name": "Liraglutide",
"lang": "EN"
},
{
"name": "リラグルチド（遺伝子組換え）",
"lang": "JP"
}
]
] | null |
NCT03096613 | [
{
"id_field": "org_study_id",
"id_value": [
"2016-798"
]
}
] | https://clinicaltrials.gov/study/NCT03096613 | Thyroid Hormone Replacement for Subclinical Hypothyroidism and Chronic Heart Failure (ThyroHeart-CHF) | Based on accumulating evidence showing that hypothyroid status is associated with poor prognosis among heart failure (HF) patients, the study is designed to evaluate whether replacement treatment with levothyroxine could have beneficial effects on patients with HF and subclinical hypothyroidism. The study is a prospect... | Efficacy and Safety of Levothyroxine (L-T4) Replacement on Exercise Capability in Chronic Systolic Heart Failure Patients With Subclinical Hypothyroidism: A 24-week, Multi-center, Open Label, Randomized, Parallel Group Trial | [
{
"description": "Levothyroxine is used to normalize the thyroid hormone level of patients allocated to levothyroxine.",
"name": "Levothyroxine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Euthyrox"
],
"type": "Drug"
}
] | [
{
"design_group_description": "The patients allocated to levothyroxine group receive levothyroxine with a starting dose of 12.5ug.",
"design_group_title": "Levothyroxine group",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervent... | [
"Heart Failure",
"Subclinical Hypothyroidism"
] | [
"Fuwai Cardiovascular Hospital"
] | [
"Henan Provincial Peoples Hospital",
"Tianjin Medical University"
] | [
[
{
"name": "左甲状腺素钠",
"lang": "CN"
},
{
"name": "Levothyroxine Sodium",
"lang": "EN"
},
{
"name": "レボチロキシンナトリウム水和物",
"lang": "JP"
}
]
] | null |
NCT00586976 | [
{
"id_field": "org_study_id",
"id_value": [
"1107-05"
]
},
{
"id_field": "secondary_id",
"id_value": [
"Contract number 1a5777"
]
}
] | https://clinicaltrials.gov/study/NCT00586976 | A Phase II/III Study of Continuous Local Anesthetic Infusion in Median Sternotomy Following Cardiac Surgery | Cardiac surgery is associated with pain in the post-operative period. We plan to conduct a study of local anesthetic, ropivacaine, infusion into the sternal wound in adult patients undergoing cardiac surgery to see if it will be safe and result in improved pain control and reduced time to extubation, duration of ICU an... | A Phase II/III Study of Continuous Local Anesthetic Infusion in Median Sternotomy Following Cardiac Surgery | [
{
"description": "0.3% ropivacaine infusion at 4 ml/hr for 64 hours.",
"name": "Ropivacaine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Normal saline infusion at 4 ml/hour for 64 hours.",
"name": "Normal saline",
"normalized_type": "3d... | [
{
"design_group_description": "Ropivicaine infusion into the sternal wound",
"design_group_title": "1",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "0.3% ropivacaine infu... | [
"Cardiac Surgery"
] | [
"Mayo Clinic"
] | [
"Stryker Nordic"
] | [
[
{
"name": "盐酸罗哌卡因",
"lang": "CN"
},
{
"name": "Ropivacaine Hydrochloride",
"lang": "EN"
},
{
"name": "ロピバカイン塩酸塩水和物",
"lang": "JP"
}
]
] | null |
NCT01324999 | [
{
"id_field": "org_study_id",
"id_value": [
"09-2326"
]
},
{
"id_field": "acronym",
"id_value": [
"SAPH"
]
}
] | https://clinicaltrials.gov/study/NCT01324999 | Tadalafil for Sarcoidosis Associated Pulmonary Hypertension | This study is designed to assess safety and efficacy of tadalafil in patients with Sarcoidosis Associated Pulmonary Hypertension.<br/>Hypothesis: Tadalafil is safe and effective in treating pulmonary hypertension in patients with Sarcoidosis | Tadalafil for Sarcoidosis Associated Pulmonary Hypertension | [
{
"description": "20mg/day for one month then 40mg/day for additional 4 months",
"name": "Tadalafil",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "Single-arm open-label proof of concept study of tadalafil in patients with sarcoidosis associated pulmonary hypertension.",
"design_group_title": "Sarcoid Associated Pulm. Hypertension",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b55615... | [
"Pulmonary Hypertension"
] | [
"The University of North Carolina at Chapel Hill"
] | [
"University of Cincinnati (Ohio)",
"United Therapeutics Corp.",
"Eli Lilly & Co."
] | [
[
{
"name": "他达拉非",
"lang": "CN"
},
{
"name": "Tadalafil",
"lang": "EN"
},
{
"name": "タダラフィル",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "aa255a58e429358e340584aad2e4a95e",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "SAPH"
}
] |
NCT00443222 | [
{
"id_field": "org_study_id",
"id_value": [
"Remicade myositis"
]
}
] | https://clinicaltrials.gov/study/NCT00443222 | Treatment With TNF Blockade, Infliximab, in Patients With Myositis | This is a 4 month open trial with TNF-blockade using infliximab (an antibody that blocks TNF) in adult patients with chronic myositis (polymyositis, dermatomyositis, inclusion body myositis) who have persisting muscle weakness and inflammatory active disease despite adequate treatment with immunosuppressives either cur... | An Open Trial With TNF Blockade With Infliximab (Remicade®), in Patients With Chronic Inflammatory Myopathies | [
{
"name": "Infliximab",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
}
] | null | [
"Refractory Myositis"
] | [
"Karolinska Institutet"
] | [
"The Medical Research Council",
"Schering-Plough Corp."
] | [
[
{
"name": "英夫利西单抗",
"lang": "CN"
},
{
"name": "Infliximab",
"lang": "EN"
},
{
"name": "インフリキシマブ（遺伝子組換え）",
"lang": "JP"
}
]
] | null |
NCT04314362 | [
{
"id_field": "org_study_id",
"id_value": [
"SOVS2020-080"
]
}
] | https://clinicaltrials.gov/study/NCT04314362 | Methods to Enhance AZR-MD-001 for Meibomian Gland Dysfunction (MGD) | Single-center, single-masked (the individual(s) performing efficacy and safety measures will be masked to treatment assignment for the patient(s) they are assessing), vehicle-controlled, randomized study. | A Single-center, Vehicle-controlled, Study to Evaluate Methods to Enhance AZR-MD-001 for Meibomian Gland Dysfunction (MGD) | [
{
"description": "AZR-MD-001 (1.0%) and suitable excipient",
"name": "AZR-MD-001 ointment/semi-solid drug",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "AZR-MD-001 ointment/semi-solid drug (1.0%)",
"design_group_title": "AZR-MD-001 Active",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "AZR-MD... | [
"Meibomian Gland Dysfunction"
] | [
"Azura Ophthalmics Ltd."
] | [
"The University of New South Wales"
] | [
[
{
"name": "AZR-MD-001",
"lang": "EN"
}
]
] | null |
NCT02065843 | [
{
"id_field": "org_study_id",
"id_value": [
"ANSI-388.427"
]
}
] | https://clinicaltrials.gov/study/NCT02065843 | Three Anxiolytic Drugs Used in Third Molar Surgery | This study was to compare the effectiveness of three drugs (Passiflora incarnata, Erythrina mulungum, Midazolam) in controlling anxiety in patients undergoing bilateral extraction of asymptomatic, impacted mandibular third molars. | Comparative Study of the Effectiveness of Three Anxiolytic Drugs Used in Third Molar Surgery | [
{
"description": "500 mg/single dose/1 hour before dental surgery",
"name": "Mulungu",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Mulungu Matusa, Erytrina mulungu"
],
"type": "Drug"
},
{
"description": "500 mg/single dose/1 hour before dental surger... | [
{
"design_group_description": "500 mg Mulungu Matusa® (Erytrina mulungu, 2 capsules of 250 mg) to be administered v.o., one hour before the surgical procedure.",
"design_group_title": "Mulungu",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a... | [
"Dental Anxiety",
"Impacted Third Molar Tooth"
] | [
"Fundação Universidade Federal de Sergipe"
] | [
"University of Campinas"
] | [
[
{
"name": "盐酸咪达唑仑",
"lang": "CN"
},
{
"name": "Midazolam Hydrochloride",
"lang": "EN"
}
],
[
{
"name": "刺桐提取物",
"lang": "CN"
},
{
"name": "Erythrina mulungu Extract",
"lang": "EN"
}
],
[
{
"name": "西番莲提取物",
"la... | null |
NCT00279422 | [
{
"id_field": "org_study_id",
"id_value": [
"291-415"
]
}
] | https://clinicaltrials.gov/study/NCT00279422 | A Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis | The purpose of this study is to compare the efficacy of visilizumab to placebo in subjects with intravenous steroid-refractory ulcerative colitis. | A Phase 2/3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis | [
{
"name": "visilizumab",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"name": "visilizumab",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_title": "placebo",
"design_group_type": "Placebo Comparator",
"design_group_type_normalized_id": "20d1ebb7d90a3d9b81daa54f73163ecb",
"intervention": [
{
"intervention_name": "visilizumab",
"intervention_type": "Drug",
"normalized_intervention_type": "3d1... | [
"Ulcerative Colitis"
] | [
"Abbott Biotherapeutics Corp."
] | [
"PDL BioPharma, Inc."
] | [
[
{
"name": "维西珠单抗",
"lang": "CN"
},
{
"name": "Visilizumab",
"lang": "EN"
}
]
] | null |
NCT01271075 | [
{
"id_field": "org_study_id",
"id_value": [
"BUCUM 2010"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2010-019344-39"
]
},
{
"id_field": "acronym",
"id_value": [
"BUCUM"
]
}
] | https://clinicaltrials.gov/study/NCT01271075 | Bilastine Updosing - Characterization of Underlying Mechanisms | This is a double-blind, triple cross-over, placebo-controlled study to assess the efficacy, mechanisms, and safety of treatment with the antihistamine bilastine in patients with cold contact urticaria (CCU).<br/>Efficacy is primarily assessed by a change in critical stimulation time thresholds (CSTT) and critical tempe... | Double-blind, Triple Cross-over, Placebo-controlled Study to Assess the Efficacy, Mechanisms, and Safety of Treatment With Bilastine 20 mg, 40 mg and 80 mg in Cold Contact Urticaria (CCU) | [
{
"description": "Single dose, oral, 20 mg, 40 mg, 80 mg each for 7 days",
"name": "Bilastine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Single dose, oral, 20 mg, 40 mg, 80 mg each for 7 days",
"name": "Bilastine",
"normalized_type": ... | [
{
"design_group_description": "A: Crossover Bilastine 20 mg, Bilastine 40 mg, Placebo, Bilastine 80 mg",
"design_group_title": "Bilastine A",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"interv... | [
"Cold Contact Urticaria"
] | [
"Charité - Universitätsmedizin Berlin"
] | [
"Faes Farma SA"
] | [
[
{
"name": "比拉斯汀",
"lang": "CN"
},
{
"name": "Bilastine",
"lang": "EN"
},
{
"name": "ビラスチン",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "BUCUM"
}
] |
NCT05578378 | [
{
"id_field": "org_study_id",
"id_value": [
"2022027"
]
}
] | https://clinicaltrials.gov/study/NCT05578378 | Cladribine Combined With G-CSF and Cytarabine as a Salvage Treatment in R/R ALL | To explore the efficiency and safety of CLAG regimen in R/R ALL | Cladribine Combined With G-CSF and Cytarabine as a Salvage Treatment in Refractory/Relapsed Acute Lymphoblastic Leukemia | [
{
"description": "Cladribine combine with cytarabine will be intravenous on days 1-5; G-CSF will be hypodermic injection on day0-5,4 weeks per cycle.",
"name": "Cladribine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Cytarabine",
"G-CSF"
],
"type": "D... | [
{
"design_group_description": "Cladribine (5 mg/m2)should be intravenous use on day 1-5, granulocyte colony-stimulating factor will be hypodermic injection using 300 μg per day on days 0-5,cytarabine (1.5 mg/m2) every 12 hours, intravenous infusion on day1-5,4 weeks per cycle.",
"design_group_title": "CLAG ... | [
"Acute Lymphoblastic Leukemia"
] | [
"The First Affiliated Hospital of Soochow University"
] | [
"Southeast University Affiliated Zhonda Hospital"
] | [
[
{
"name": "克拉屈滨",
"lang": "CN"
},
{
"name": "Cladribine",
"lang": "EN"
},
{
"name": "クラドリビン",
"lang": "JP"
}
]
] | null |
NCT02565511 | [
{
"id_field": "org_study_id",
"id_value": [
"CAPI015A2201J"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2015-002715-15"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"1UF1AG0... | https://clinicaltrials.gov/study/NCT02565511 | A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease | The purpose of this study was to test whether two investigational drugs called CAD106 and CNP520, administered separately, could slow down the onset and progression of clinical symptoms associated with Alzheimer's disease (AD) in participants at the risk to develop clinical symptoms based on their age and genotype. | A Randomized, Double-blind, Placebo-controlled, Two-cohort, Parallel Group Study to Evaluate the Efficacy of CAD106 and CNP520 in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease. | [
{
"description": "Participants will be given i.m. injections at Weeks 1, 7, 13 and quarterly i.m. injections (every 13 weeks) thereafter, until the last injection 3 month prior to completion of the Treatment Epoch.",
"name": "CAD106 Immunotherapy",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
... | [
{
"design_group_description": "CAD106 (450 µg) + Alum (450 µg) intra-muscular injection at Weeks 1, 7, 13 and every 13 weeks thereafter",
"design_group_title": "Cohort I (CAD106)",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"interv... | [
"Alzheimers Disease"
] | [
"Novartis Pharmaceuticals Corp."
] | [
"Banner Alzheimer's Institute",
"Amgen, Inc.",
"National Institute on Aging"
] | [
[
{
"name": "Amilomotide",
"lang": "EN"
}
],
[
{
"name": "Umibecestat",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "a8aa293e8a9249598528e5a0adad8828",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "GS1"
}
] |
NCT01488136 | [
{
"id_field": "org_study_id",
"id_value": [
"2010DM03"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2011-005011-93"
]
}
] | https://clinicaltrials.gov/study/NCT01488136 | Use of Diazoxide in Acute Hypoglycaemia | The investigators know that intensive insulin therapy and tight glucose control is associated with reduction of diabetic complications. However, many patients on insulin don't achieve this because of the risk and the fear of hypoglycaemia (too low blood glucose).<br/>There has been a lot of work done recently looking a... | Use of Diazoxide in Acute Hypoglycaemia | [
{
"description": "Diazoxide 7mg/kg, given 2 hours before the start of the clamp study",
"name": "Diazoxide",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Eudemine (Diazoxide)"
],
"type": "Drug"
},
{
"description": "Lactose Ph capsules (Placebo)",
... | [
{
"design_group_description": "Oral diazoxide 7 mg/kg",
"design_group_title": "Diazoxide",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"intervention_description": "Diazoxide 7mg/kg, given 2 hou... | [
"Type 1 Diabetes"
] | [
"University Of Dundee"
] | [
"Juvenile Diabetes Research Foundation"
] | [
[
{
"name": "二氮嗪",
"lang": "CN"
},
{
"name": "Diazoxide",
"lang": "EN"
},
{
"name": "ジアゾキシド",
"lang": "JP"
}
]
] | null |
NCT05118490 | [
{
"id_field": "org_study_id",
"id_value": [
"IRB00298999"
]
},
{
"id_field": "acronym",
"id_value": [
"1 to 3"
]
}
] | https://clinicaltrials.gov/study/NCT05118490 | Comparing Treatment Completion Of Daily Rifapentine & Isoniazid For One Month (1HP) To Weekly High Dose Rifapentine & Isoniazid For 3 Months (3HP) In Persons Living With HIV and in Household Contacts of Recently Diagnosed Tuberculosis Patients | A multicenter, randomized, stratified, open-label, phase IV trial among HIV-positive persons (PLHIV) on antiretroviral therapy (ART), or HIV-negative household contacts of patients with rifampicin-sensitive pulmonary tuberculosis (TB), who do not have evidence of active TB. | A Randomized Trial Comparing Treatment Completion of Daily Rifapentine & Isoniazid for One Month (1HP) To Weekly Rifapentine & Isoniazid For 3 Months (3HP) In Persons Living With HIV and in HIV-negative Household Contacts of Recently Diagnosed Tuberculosis Patients, The "One To Three" Trial | [
{
"description": "Arm A: isoniazid (300mg) and rifapentine (600mg) daily for 4 weeks (1HP)",
"name": "Daily rifapentine and isoniazid for 4 weeks",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Arm B: isoniazid (900mg) and rifapentine (900mg) week... | [
{
"design_group_title": "Group 1: People living with HIV infection without active TB",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Arm A: isoniazid (300mg) and rifapentine (... | [
"HIV Seropositivity",
"Tuberculosis",
"Household Contact"
] | [
"The Aurum Institute"
] | [
"The Johns Hopkins University"
] | [
[
{
"name": "利福喷丁",
"lang": "CN"
},
{
"name": "Rifapentine",
"lang": "EN"
}
],
[
{
"name": "异烟肼",
"lang": "CN"
},
{
"name": "Isoniazid",
"lang": "EN"
},
{
"name": "イソニアジド",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "1 to 3"
}
] |
NCT03998709 | [
{
"id_field": "org_study_id",
"id_value": [
"19-003325"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"R01DK078646"
]
}
] | https://clinicaltrials.gov/study/NCT03998709 | Effect of Fasting Free Fatty Acids and Fasting Glucose on 1st and 2nd Phase Insulin Secretion | Researchers are trying to determine how changes in fasting glucose and free fatty acids (products released from fat) affect insulin secretion. | Effect of Fasting Free Fatty Acids and Fasting Glucose on 1st and 2nd Phase Insulin Secretion | [
{
"description": "Somatostatin will be used to inhibit endogenous insulin secretion on either study day in both arms of the study",
"name": "Somatostatin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"pancreatic clamp"
],
"type": "Drug"
},
{
"descript... | [
{
"design_group_description": "People with normal fasting glucose and normal fasting FFA (normal fasting glucose / normal glucose tolerance - NFG / NGT) will be studied on 2 occasions. On one occasion they will receive saline overnight and on the other they will receive intralipid and dextrose to raise fasting ... | [
"Healthy"
] | [
"Mayo Clinic"
] | [
"National Institute of Diabetes & Digestive & Kidney Diseases"
] | [
[
{
"name": "醋酸生长抑素",
"lang": "CN"
},
{
"name": "Somatostatin Acetate",
"lang": "EN"
}
]
] | null |
NCT04908982 | [
{
"id_field": "org_study_id",
"id_value": [
"AS1H"
]
}
] | https://clinicaltrials.gov/study/NCT04908982 | Aspirin for the Prevention of Preeclampsia in Women With Stage 1 Hypertension | In 2017, the American College of Cardiology and the American Heart Association changed the diagnostic criteria for hypertension in non-pregnant adults. The parameters for the diagnosis of stage 1 hypertension were revised from a systolic blood pressure (BP) of 140 to 130 mm Hg and a diastolic BP of 90 to 80 mm Hg. Base... | Aspirin for the Prevention of Preeclampsia in Women With Stage 1 Hypertension: A Pilot Study | [
{
"description": "81mg aspirin daily beginning between 12 and 16 weeks of pregnancy and continuing until delivery.",
"name": "Aspirin 81mg",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "Participants in this arm will be instructed to take 1 81mg aspirin daily beginning between weeks 12 and 16 of pregnancy and continuing until delivery.",
"design_group_title": "Aspirin",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b556156... | [
"Pre-Eclampsia"
] | [
"Eastern Virginia Medical School"
] | [
"AMAG Pharmaceuticals, Inc."
] | [
[
{
"name": "阿司匹林",
"lang": "CN"
},
{
"name": "Aspirin",
"lang": "EN"
},
{
"name": "サリチル酸",
"lang": "JP"
}
]
] | null |
NCT05803096 | [
{
"id_field": "org_study_id",
"id_value": [
"2021P-000715"
]
}
] | https://clinicaltrials.gov/study/NCT05803096 | Self-Administered Nitrous Oxide (SANO) During Transrectal Prostate Biopsy to Reduce Patient Anxiety and Pain | Transrectal prostate biopsy is a commonly performed ambulatory procedure for diagnosing prostate cancer. Prostate biopsy are associated with pain or anxiety. Nitrous oxide (or laughing gas) is a well-known inhaled anesthetic which is frequently used in dental offices and for pediatric procedures to alleviate a patient'... | Self-Administered Nitrous Oxide (SANO) During Transrectal Prostate Biopsy to Reduce Patient Anxiety and Pain | [
{
"description": "Nitrous oxide administered at concentrations of mild sedation (20-45%) for the duration of prostate biopsy.",
"name": "Self-Administered Nitrous Oxide",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"nitrous oxide"
],
"type": "Drug"
},
{
... | [
{
"design_group_description": "Patients will receive SANO in addition to periprostatic bupivacaine nerve block for the duration of prostate biopsy.<br/>After the Urologist describes the procedure, the SANO group will have nitrous oxide turned on to 30%, ensuring that the patient is relaxed but still conversant ... | [
"Prostate Disease",
"Malignancy",
"Benign Prostatic Hyperplasia",
"Prostate Cancer",
"Prostate Adenocarcinoma",
"Anxiety and Fear",
"Pain"
] | [
"Beth Israel Deaconess Medical Center, Inc."
] | [
"The Brigham & Women's Hospital, Inc."
] | [
[
{
"name": "Nitrous Oxide",
"lang": "EN"
}
]
] | null |
NCT02202304 | [
{
"id_field": "org_study_id",
"id_value": [
"CHLOVADENT"
]
}
] | https://clinicaltrials.gov/study/NCT02202304 | The Effects of Chlorhexidine/Thymol Varnish on Partial Denture Patient | Cervitec, a chlorhexidine based varnished has been proven to reduce caries risk in younger populations. This study wants to investigate if the use of this product would reduce the risk of losing abutment teeth on patients that are wearing partial dentures as the literature has proven that these teeth are more prone to ... | The Effects of Chlorhexidine/Thymol Varnish on the Abutment Teeth in Partial Denture Wearers. | [
{
"description": "This will be applied on abutment teeth on partial denture wearers every 3 months during a period of 2 years.",
"name": "Chlorhexidine/Thymol varnish",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Cervitec Plus (1% chlorhexidine plus 1% thymol)"
... | [
{
"design_group_description": "Participants to the study will receive an application of either the placebo or the product being studied every 3 months. This will be applied on all abutment teeth using a microbrush by \"painting\" it over the surfaces of these teeth.",
"design_group_title": "Chlorhexidine/Th... | [
"Periodontal Disease",
"Caries"
] | [
"University of Aberdeen"
] | [
"Ivoclar Vivadent AG"
] | [
[
{
"name": "葡萄糖氯己定",
"lang": "CN"
},
{
"name": "Chlorhexidine gluconate",
"lang": "EN"
},
{
"name": "クロルヘキシジングルコン酸塩",
"lang": "JP"
}
]
] | null |
NCT02283905 | [
{
"id_field": "org_study_id",
"id_value": [
"B2014:032"
]
},
{
"id_field": "acronym",
"id_value": [
"BLASTO"
]
}
] | https://clinicaltrials.gov/study/NCT02283905 | Amphotericin-B and Voriconazole for Pulmonary Blastomycosis | All patients with pulmonary blastomycosis requiring mechanical ventilation will have their blood concentrations measured for the antifungal drugs, amphotericin-B and voriconazole; as well as an analysis of the susceptibility of their infecting species of blastomyces. This information will then be analyzed relative to t... | Case Series of Continuously-infused Amphotericin-B and Follow-up Voriconazole Therapy for Severe Blastomycosis Pulmonary Infections | [
{
"description": "continuously infused",
"name": "amphotericin-B",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Fungizone"
],
"type": "Drug"
},
{
"description": "intravenously or orally administered",
"name": "voriconazole",
"normalized_type":... | [
{
"design_group_description": "Treatment with a 24 hour continuous infusion of amphotericin B deoxycholate at 1.0 mg/kg/day for a total dose of at least 1 g (i.e. <br/> 14 days); and then the patient is stepped down to voriconazole 6 mg/kg i.v. q12h for 2 doses, then 4 mg/kg q12h either i.v. or orally as approp... | [
"Blastomycosis"
] | [
"University of Manitoba"
] | [
"Pfizer Inc."
] | [
[
{
"name": "两性霉素B",
"lang": "CN"
},
{
"name": "Amphotericin B",
"lang": "EN"
},
{
"name": "アムホテリシンB",
"lang": "JP"
}
],
[
{
"name": "伏立康唑",
"lang": "CN"
},
{
"name": "Voriconazole",
"lang": "EN"
},
{
"... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "BLASTO"
}
] |
NCT00288782 | [
{
"id_field": "org_study_id",
"id_value": [
"Mirtazapine_Occupancy_01_2005"
]
}
] | https://clinicaltrials.gov/study/NCT00288782 | PET Neuroimaging of [11C]Mirtazapine | Recent studies show that 25 - 30% of depressed patients never fully recover, resulting in a treatment-resistant condition. Thus, depression is a major cause of human suffering. We are interested in finding new ways of identifying and alleviating treatment-resistant depression, and we believe that recent advances in bra... | Receptor Occupancy Determined by PET Neuroimaging of [11C]Mirtazapine in Healthy Humans | [
{
"name": "Mirtazapine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
}
] | null | [
"Mental Disorders",
"Mood Disorders",
"Affective Disorders",
"Depressive Disorders"
] | [
"University of Aarhus"
] | [
"Danish Medical Research Council"
] | [
[
{
"name": "米氮平",
"lang": "CN"
},
{
"name": "Mirtazapine",
"lang": "EN"
},
{
"name": "ミルタザピン",
"lang": "JP"
}
]
] | null |
NCT04657679 | [
{
"id_field": "org_study_id",
"id_value": [
"STUDY00003100"
]
},
{
"id_field": "acronym",
"id_value": [
"LEANORA"
]
}
] | https://clinicaltrials.gov/study/NCT04657679 | Pharmacokinetics and Pharmacogenomics of Ribociclib in Race-based Cohorts | The aim is to determine the pharmacological and biochemical association between ribociclib exposure and CYP3A variants in African American/Blacks and Non-Hispanic White patients. The investigators hypothesize that patients treated with ribociclib who are CYP3A5 poor metabolizers may be exposed to higher levels of riboc... | evaLuation of Variations pharmacokinEtics and phArmacogeNOmics of Ribociclib in rAce-based Cohorts: The LEANORA Study | [
{
"description": "Patients will receive ribociclib 600 mg oral (PO) daily for 21 consecutive days of 28-day cycles and endocrine therapy with either letrozole or fulvestrant. Fulvestrant 500 mg intramuscular (IM) will be administered on days 1, 15, 29 of cycle one, and then monthly. Letrozole 2.5 mg oral daily ... | [
{
"design_group_description": "Subject who self identify as African American or Black with metastatic HR+/HER2- advanced breast cancer (estimate 3 participants who are CYP3A5 poor metabolizers and approximately 15 participants who are CYP3A5 intermediate or normal metabolizers)",
"design_group_title": "Afri... | [
"Breast Cancer"
] | [
"Georgetown University"
] | [
"National Cancer Institute",
"The Breast Cancer Research Foundation",
"MedStar Research Institute"
] | [
[
{
"name": "琥珀酸瑞波西利",
"lang": "CN"
},
{
"name": "Ribociclib Succinate",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "5e22eaaa5252d54e325022e8ed294428",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "LEANORA"
}
] |
NCT06455813 | [
{
"id_field": "org_study_id",
"id_value": [
"Laxatives26092019"
]
}
] | https://clinicaltrials.gov/study/NCT06455813 | What Laxative Should be Used After Hip Fracture Surgery? | To conduct a randomized clinical trial to determine how best to prevent constipation after hip fracture surgery using laxatives. | Oral Laxatives After Hip Fracture Surgery: A Randomised Controlled Trial | [
{
"description": "The patients' stool frequency, degree of constipation and side effects of the medication as well as pain, nausea and flatulence are scored once a day using the Bristol Stool Scale, Verbal Rank Scale and Patient Assessment of Constipation symptoms Questionnaire. If the first defecation has not ... | [
{
"design_group_description": "Powder for oral solution in sachet Macrogol 3350 and electrolytes (ATC code A06AD65) which is administered orally as the content of 2 sachets daily (in the evening) during admission",
"design_group_title": "Macrogol 3350 and electrolytes.",
"design_group_type": "Active Com... | [
"Hip Fractures"
] | [
"Odense University Hospital"
] | [
"InnovationsFonden"
] | [
[
{
"name": "比沙可啶",
"lang": "CN"
},
{
"name": "Bisacodyl",
"lang": "EN"
},
{
"name": "ビサコジル",
"lang": "JP"
}
]
] | null |
NCT01490398 | [
{
"id_field": "org_study_id",
"id_value": [
"2011-0865"
]
},
{
"id_field": "acronym",
"id_value": [
"RESERVE"
]
}
] | https://clinicaltrials.gov/study/NCT01490398 | Rosuvastatin Effect on Serial Echocardiographic Measurement of Coronary Flow Velocity Reserve | In ASCOT study, lipid lowering with a statin provided additional beneficial effects in hypertensive patients with average levels of serum total cholesterol. However, the underlying mechanism of statins to improve clinical outcomes in hypertension is unclear and the effect of statins on coronary flow reserve (CFR) has n... | Effect of Rosuvastatin on Coronary Flow Reserve in Hypertensive Patients | [
{
"description": "After baseline assessment, the starting dose of rosuvastatin 10 mg will be given to study patients. If tolerated and LDL-C is > 100mg/dL after 2-4 weeks, the dose will be increased to 20 mg. Rosuvastatin treatment is scheduled to continue for 1 year without no further dose titration, and each ... | [
{
"design_group_description": "Rosuvastatin 10mg qd for 12 months.",
"design_group_title": "Rosuvastatin",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "After baseline ass... | [
"Hypertension",
"Cardiovascular Risk Factors"
] | [
"Asan Medical Center"
] | [
"AstraZeneca PLC"
] | [
[
{
"name": "瑞舒伐他汀钙",
"lang": "CN"
},
{
"name": "Rosuvastatin Calcium",
"lang": "EN"
},
{
"name": "ロスバスタチンカルシウム",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "RESERVE"
}
] |
NCT04105764 | [
{
"id_field": "org_study_id",
"id_value": [
"elite NMB"
]
}
] | https://clinicaltrials.gov/study/NCT04105764 | Deep NMB in Ambulatory Gynecological Laparoscopy | Gynecological laparoscopic surgery is commonly performed as an ambulatory basis for the aim of rapid discharge, reduce hospital stay with reduced costs and to improve postoperative QOR [1,2]. However, the creation of pneumoperitoneum during laparoscopy may cause postoperative pain and other physiological changes [3], w... | Deep Neuromuscular Blockade to Improve Postoperative Quality of Recovery in Ambulatory Gynaecologic Laparoscopy | [
{
"description": "DEEP block to PTC 1-3",
"name": "Rocuronium",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Neuromuscular blocker"
],
"type": "Drug"
},
{
"description": "MODERATE block to TOF1-2",
"name": "Rocuronium bromide",
"normalized_typ... | [
{
"design_group_description": "In the deep NMB-group, a PTC of 1 to 2 twitches was maintained, and NMB was reversed with sugammadex at the end of surgery.",
"design_group_title": "DEEP BLOCK",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76... | [
"Muscle Relaxation"
] | [
"Ain Shams University"
] | [
"Elite Medical Center"
] | [
[
{
"name": "罗库溴铵",
"lang": "CN"
},
{
"name": "Rocuronium Bromide",
"lang": "EN"
},
{
"name": "ロクロニウム臭化物",
"lang": "JP"
}
]
] | null |
NCT02145611 | [
{
"id_field": "org_study_id",
"id_value": [
"CLAF237ABR07T"
]
}
] | https://clinicaltrials.gov/study/NCT02145611 | Vildagliptin vs. Glibenclamide in Endothelial Function in Type 2 Diabetes and Hypertension | Cardiovascular disease is a major public health problem in our country. Among the causes of cardiovascular diseases are High Blood Pressure (HBP) and Diabetes Mellitus (DM). Type 2 diabetes (DM2) is associated with a twofold risk of cardiovascular disease, and endothelial dysfunction is an early marker of vascular comp... | 12-week Randomized Study to Compare the Effect of Vildagliptin vs. Glibenclamide Associated to Metformin in Endothelial Function in Patients With Type 2 Diabetes and Hypertension | [
{
"description": "Glibenclamide",
"name": "Glibenclamide",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Daonil"
],
"type": "Drug"
},
{
"description": "Vildagliptin",
"name": "Vildagliptin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b"... | [
{
"design_group_description": "Vildagliptin: Dosage: 100 mg/day; Duration: 12 weeks",
"design_group_title": "vildagliptin",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"intervention_description... | [
"Type 2 Diabetes Mellitus",
"Hypertension",
"Endothelial Dysfunction"
] | [
"Hospital de Base"
] | [
"Novartis AG"
] | [
[
{
"name": "维格列汀",
"lang": "CN"
},
{
"name": "Vildagliptin",
"lang": "EN"
},
{
"name": "ビルダグリプチン",
"lang": "JP"
}
],
[
{
"name": "格列本脲",
"lang": "CN"
},
{
"name": "Glyburide",
"lang": "EN"
},
{
"name":... | null |
NCT02601976 | [
{
"id_field": "org_study_id",
"id_value": [
"GETZ-UNIP- 4010810"
]
},
{
"id_field": "acronym",
"id_value": [
"EUROP"
]
}
] | https://clinicaltrials.gov/study/NCT02601976 | Evaluation of Unipeg® for Response and Ongoing Safety in Pakistani Population | Hepatitis C is a global problem, prevalent in developed as well as in the developing countries. New treatment regimens using PegInterferon in combination with ribavirin has led to improved sustained viral response rates for some genotypes. A single arm, open labeled, multicentre trial was conducted to evaluate the resp... | Response Evaluation of Peginterferon Alfa-2a 180µg 20kDa (Unipeg®) Plus Ribavirin (Ribazole®) in Treatment naïve Pakistani Population With Chronic Hepatitis C Infection | [
{
"description": "PegInterferon alfa-2a 180mcg 20kDa administered subcutaneously once weekly for 24 weeks in genotype 3 and for 48 weeks in genotype 1 patients.",
"name": "Peginterferon alfa-2a",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Unipeg"
],
"type":... | [
{
"design_group_description": "PegInterferon alfa-2a subcutaneously once weekly Ribavirin administered orally according to the body weight",
"design_group_title": "PegInterferon alfa-2a and Ribavirin",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22c... | [
"Hepatitis C"
] | [
"Getz Pharma Pakistan (Pvt) Ltd."
] | [
"Dimension Research"
] | [
[
{
"name": "聚乙二醇干扰素α-2a",
"lang": "CN"
},
{
"name": "Peginterferon alfa-2a",
"lang": "EN"
},
{
"name": "ペグインターフェロン アルファ‐2a（遺伝子組換え）",
"lang": "JP"
}
],
[
{
"name": "利巴韦林",
"lang": "CN"
},
{
"name": "Ribavirin",
"lang... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "5925598ee84ee4588e55389238a222a8",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "EUROP"
}
] |
NCT06754163 | [
{
"id_field": "org_study_id",
"id_value": [
"2024/254"
]
},
{
"id_field": "acronym",
"id_value": [
"STEP@STAH"
]
}
] | https://clinicaltrials.gov/study/NCT06754163 | Evaluating the Effect of the STEP@STAH Semaglutide Protocol on the Physical Health Measures of Atypical Antipsychotic-Treated Patients | A significant number of patients who are prescribed anti-psychotic medication such as clozapine are considered as clinically obese (BMI >35.0). While this may be associated with the appetite promoting properties of the drug, other factors including apathy and lack of physical activity and exercise can exacerbate the we... | Pilot Study Designed in a Phase IV Clinical Trial Framework: Evaluating the Effect of the STEP@STAH Semaglutide Protocol on the Physical Health Measures of Atypical Antipsychotic-Treated Patients in a Secure Mental Healthcare Setting | [
{
"description": "Wegovy (semaglutide) will be provided as an induction dose of 0.25 mg, titrated up every 4 weeks to 0.5 mg, 1.0 mg, 1.7 mg and 2.4 mg, will be given, with a maintenance dose of 2.4 mg or to the maximum tolerated dose.<br/>To reduce the likelihood of gastrointestinal symptoms, the dose should b... | [
{
"design_group_description": "The primary aim of the study is to assess the impact of treatment with semaglutide, in combination with a healthy lifestyle (including diet and exercise) on the physical health measures of patients in St Andrew's who have atypical antipsychotic induced weight gain. There is signif... | [
"Obesity and Obesity-related Medical Conditions",
"Psychiatric Disorders"
] | [
"St. Andrew's Healthcare"
] | [
"Loughborough University"
] | [
[
{
"name": "司美格鲁肽 (诺和诺德)",
"lang": "CN"
},
{
"name": "Semaglutide (Novo Nordisk)",
"lang": "EN"
},
{
"name": "セマグルチド（遺伝子組換え）",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "STEP@STAH"
}
] |
NCT02407314 | [
{
"id_field": "org_study_id",
"id_value": [
"ESR-14-10020"
]
}
] | https://clinicaltrials.gov/study/NCT02407314 | Ticagrelor and Peripheral Arterial Disease | This is an interventional study assessing the effectiveness of Ticagrelor on the reduction of thrombus burden using optical coherence tomography in patients undergoing peripheral artery stenting. | Impact of Ticagrelor and Aspirin Versus Clopidogrel and Aspirin in Patients With Claudication and Peripheral Arterial Disease (PAD): Thrombus Burden Assessed by Optical Coherence Tomography | [
{
"description": "Percutaneous peripheral intervention is a common procedure performed by cardiologists to revascularize peripheral arterial lesions in patients (stent placement). This procedure is considered standard of care and is not experimental.",
"name": "Percutaneous Peripheral Intervention",
"no... | [
{
"design_group_description": "Clopidogrel 75 mg + aspirin 81 mg for the first month followed by aspirin 81 mg alone for months 2-6 months post percutaneous peripheral intervention (PPI) intervention assessed by optical coherence tomography (OCT) ankle brachial index (ABI) and six minute walk distance.",
"d... | [
"Peripheral Arterial Disease"
] | [
"Medcath of Little Rock LLC"
] | [
"The University of Alabama at Birmingham",
"University of Texas Health Science Center At San Antonio"
] | [
[
{
"name": "替格瑞洛",
"lang": "CN"
},
{
"name": "Ticagrelor",
"lang": "EN"
},
{
"name": "チカグレロル",
"lang": "JP"
}
],
[
{
"name": "阿司匹林",
"lang": "CN"
},
{
"name": "Aspirin",
"lang": "EN"
},
{
"name": "サリチル... | null |
NCT04051723 | [
{
"id_field": "org_study_id",
"id_value": [
"KY 2018-066-02-2"
]
}
] | https://clinicaltrials.gov/study/NCT04051723 | Pre-emptive Scalp Infiltration With Dexamethasone Plus Ropivacaine for Post-Craniotomy Pain in Children | At present, pediatric postoperative analgesia has not been fully understood and controlled, particularly craniotomy surgery. On the one hand, professional evaluation of postoperative pain for young children is difficult; on the other hand, the particularity of craniotomy adds (such as consciousness obstacle, sleepiness... | Pre-emptive Scalp Infiltration With Dexamethasone Plus Ropivacaine for Post-Craniotomy Pain in Children | [
{
"description": "The local infiltration solution containing 0.25mg Dexamethasone and 2mg ropivacaine per milliliter. The total volume is 20 ml. The assigned solution will be injected subcutaneously by surgeons along the incision and throughout the entire thickness of the scalp before skin incision. The volume ... | [
{
"design_group_description": "Patients in the dexamethasone plus ropivacaine group will receive a peri-incisional scalp infiltration with 0.025% dexamethasone and 0.2% ropivacaine and normal saline miscible liquids.",
"design_group_title": "The dexamethasone plus ropivacaine group",
"design_group_type"... | [
"Pain, Postoperative",
"Children"
] | [
"Beijing Tiantan Hospital"
] | [
"Beijing Children Hospital Group Co. Ltd."
] | [
[
{
"name": "盐酸罗哌卡因",
"lang": "CN"
},
{
"name": "Ropivacaine Hydrochloride",
"lang": "EN"
},
{
"name": "ロピバカイン塩酸塩水和物",
"lang": "JP"
}
],
[
{
"name": "地塞米松",
"lang": "CN"
},
{
"name": "Dexamethasone",
"lang": "EN"
... | null |
NCT07346079 | [
{
"id_field": "org_study_id",
"id_value": [
"2025P001469"
]
},
{
"id_field": "secondary_id",
"id_value": [
"2025P001469"
]
}
] | https://clinicaltrials.gov/study/NCT07346079 | Purified Cortrophin® Gel Efficacy and Safety Study of 2 Dose Levels in Patients With Acute Gout Flares | This is a randomized, multicenter, double-blind, single administration study to investigate the efficacy and safety of 2 dosing regimens of Purified Cortrophin® Gel in the treatment of an acute gouty arthritis flare.<br/>The study consists of three periods: an optional pre-screening period, a double-blind treatment per... | A Randomized, Multicenter, Double-blind, Efficacy and Safety Study of 2 Dose Levels of Purified Cortrophin® Gel in Patients With Acute Gouty Arthritis Flares | [
{
"description": "This will be the 40 U dose of the purified Cortophin Gel",
"name": "Purified Cortophin Gel, 40 U",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "This will be the 80 U dose of the purified Cortophin Gel",
"name": "Purified Cor... | [
{
"design_group_description": "Patients in this arm will receive the 40 U dose at Day 0",
"design_group_title": "Purified Cortophin Gel 40 U",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"interventi... | [
"Gout Arthritis",
"Gout Flare",
"Gout"
] | [
"The Massachusetts General Hospital"
] | [
"ANI Pharmaceuticals, Inc."
] | [
[
{
"name": "促皮质素",
"lang": "CN"
},
{
"name": "Corticotropin",
"lang": "EN"
}
]
] | null |
NCT01390246 | [
{
"id_field": "org_study_id",
"id_value": [
"10-217"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"R01DA030998"
]
}
] | https://clinicaltrials.gov/study/NCT01390246 | Bupropion for Smoking Cessation During Pregnancy | This is a prospective, double-blind placebo-controlled randomized pilot trial of the preliminary safety and efficacy of bupropion SR in combination with behavioral counseling for smoking cessation during pregnancy. | Bupropion for Smoking Cessation During Pregnancy | [
{
"description": "Bupropion SR 150 mg tablet",
"name": "Bupropion SR",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Zyban",
"buproban"
],
"type": "Drug"
},
{
"description": "35-min counseling by trained research nurse",
"name": "Smoking Cess... | [
{
"design_group_description": "Bupropion SR and smoking cessation counseling Subjects received Bupropion SR 150 mg tablet orally twice daily (BID) for 12 weeks. Subjects were instructed to begin using study medication (bupropion SR 150 mg orally for 3 days, then BID for 4 days) on study visit day 1, which was a... | [
"Pregnancy Related",
"Tobacco Use Disorder"
] | [
"University of Texas Medical Branch"
] | [
"National Institute on Drug Abuse",
"University of Connecticut Health Center"
] | [
[
{
"name": "盐酸安非他酮",
"lang": "CN"
},
{
"name": "Bupropion Hydrochloride",
"lang": "EN"
}
]
] | null |
NCT02547844 | [
{
"id_field": "org_study_id",
"id_value": [
"EfaRiLipidomics"
]
}
] | https://clinicaltrials.gov/study/NCT02547844 | Evolution of Plasma Lipid Profile in Patients With HIV1 Who Change Atripla to Eviplera Compared to Continue With Atripla | To compare the lipidomic profile in patients with HIV-1 with viral suppression changing efavirenz + emtricitabine + tenofovir (Atripla) to rilpivirine + emtricitabine + tenofovir (Eviplera®) versus a group of patients that continue with Atripla®. | Open Randomized Study to Assess the Evolution of Plasma Lipid Profile by Lipidomic in Patients Infected With Human Immunodeficiency Virus (HIV-1) With Viral Suppression That Change Atripla® to Eviplera® Compared to Continue With Atripla® | [
{
"name": "efavirenz + emtricitabina + tenofovir",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"atripla"
],
"type": "Drug"
},
{
"name": "rilpivirina + emtricitabina + tenofovir",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name":... | [
{
"design_group_description": "Patients assigned to the control group will continue receiving the same medication than before to be included in the study: Atripla (efavirenz + emtricitabina + tenofovir)",
"design_group_title": "efavirenz + emtricitabina + tenofovir",
"design_group_type": "Active Compara... | [
"HIV-1"
] | [
"Vall DHebron University Hospital"
] | [
"Gilead Sciences, Inc."
] | [
[
{
"name": "恩曲他滨/盐酸利匹韦林/富马酸磷丙替诺福韦",
"lang": "CN"
},
{
"name": "Emtricitabine/Rilpivirine Hydrochloride/Tenofovir Alafenamide Fumarate",
"lang": "EN"
},
{
"name": "リルピビリン塩酸塩/テノホビル アラフェナミドフマル酸塩/エムトリシタビン",
"lang": "JP"
}
]
] | null |
NCT01973283 | [
{
"id_field": "org_study_id",
"id_value": [
"#6470/7289R"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"K23MH099097-01A1"
]
}
] | https://clinicaltrials.gov/study/NCT01973283 | Antidepressant Response in the Treatment of Depressive Symptoms and Frailty Characteristics in Older Adults | The goal of this open-administration treatment study of citalopram (or duloxetine) is to evaluate the effect of antidepressant medication on treating the syndrome of "frailty" in older adults with depressive symptoms. Patients with significant depressive symptoms (defined as CES-D (Center for Epidemiological Studies - ... | Antidepressant Response in the Treatment of Depressive Symptoms and Frailty Characteristics in Older Adults | [
{
"description": "If patient has a history of non-response or cannot tolerate escitalopram and/or duloxetine, then they will be treated openly with an approved antidepressant.",
"name": "Antidepressant Medication",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Duloxet... | [
{
"design_group_description": "Participants are treated with a flexible-dose antidepressant medication for a period of 8 weeks.",
"design_group_title": "Medication Treatment",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"interventio... | [
"Major Depressive Disorder",
"Dysthymic Disorder",
"Depressive Disorder, NOS"
] | [
"The New York State Psychiatric Institute"
] | [
"National Institute of Mental Health"
] | [
[
{
"name": "草酸艾司西酞普兰",
"lang": "CN"
},
{
"name": "Escitalopram Oxalate",
"lang": "EN"
},
{
"name": "エスシタロプラムシュウ酸塩",
"lang": "JP"
}
]
] | null |
NCT00205699 | [
{
"id_field": "org_study_id",
"id_value": [
"NIMH"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"R01MH072912"
]
},
{
"id_field": "acronym",
"id_value": [
"MEAC"
]
}
] | https://clinicaltrials.gov/study/NCT00205699 | Metabolic Effects of Antipsychotics in Children | The project aims to describe and compare the outcome of 12 weeks of prospective, randomized treatment with olanzapine, risperidone or aripiprazole on insulin action in skeletal muscle, liver and adipose tissue, abdominal fat mass, total body and fat-free mass, efficacy for symptoms of aggression and non-metabolic adver... | Metabolic Effects of Antipsychotics in Children | [
{
"description": "randomized to begin 12 week trial of risperidone",
"name": "risperidone",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Risperdal"
],
"type": "Drug"
},
{
"description": "randomized to begin 12 week trial of olanzapine",
"name": "o... | [
{
"design_group_description": "Participants in this group will be randomized to flexibly-dosed treatment with aripiprazole.",
"design_group_title": "aripiprazole",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
... | [
"Aggression",
"Attention Deficit-Hyperactivity",
"Oppositional Defiant Disorder",
"Pervasive Development Disorders",
"Bipolar Disorder"
] | [
"Washington University School of Medicine"
] | [
"National Institute of Mental Health"
] | [
[
{
"name": "阿立哌唑",
"lang": "CN"
},
{
"name": "Aripiprazole",
"lang": "EN"
},
{
"name": "アリピプラゾール水和物",
"lang": "JP"
}
],
[
{
"name": "利培酮",
"lang": "CN"
},
{
"name": "Risperidone",
"lang": "EN"
},
{
"na... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "eea2d8e245232aa5055ae8229428d09e",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "MEAC"
}
] |
NCT04713358 | [
{
"id_field": "org_study_id",
"id_value": [
"2020-sx004"
]
},
{
"id_field": "secondary_id",
"id_value": [
"2020-sx004"
]
}
] | https://clinicaltrials.gov/study/NCT04713358 | Effect of Nalmefene on the Quality of Resuscitation in Patients Under General Anesthesia | Postoperative recovery is an important part of the patient's experience. A good recovery period is an important guarantee for the recovery of postoperative organs and functions after surgery. However, the delay in awakening after general anesthesia remains one of the biggest challenges facing anesthesiologists. The tim... | Effect of Nalmefene on the Quality of Resuscitation in Patients Under General Anesthesia | [
{
"description": "Immediately Intravenous injection of Nalmefene (0.25 g/kg, plus normal saline to 1ml) after surgery",
"name": "Nalmefene",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Immediately Intravenous injection of normal saline 1ml after... | [
{
"design_group_description": "for the nalmefene group, immediately Intravenous injection of Nalmefene (0.25 g/kg, plus normal saline to 1ml) after surgery",
"design_group_title": "Nalmefene group",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61... | [
"Resuscitation"
] | [
"Shanghai Renji Hospital Management Co., Ltd."
] | [
"The First Affiliated Hospital of Zhengzhou University",
"First Affiliated Hospital of Guangxi Medical University"
] | [
[
{
"name": "盐酸纳美芬",
"lang": "CN"
},
{
"name": "Nalmefene Hydrochloride",
"lang": "EN"
},
{
"name": "ナルメフェン塩酸塩水和物",
"lang": "JP"
}
]
] | null |
NCT03219294 | [
{
"id_field": "org_study_id",
"id_value": [
"988210-2"
]
}
] | https://clinicaltrials.gov/study/NCT03219294 | Does Deep Neuromuscular Blockade Improve Operating Conditions During Total Hip Replacements? | During many surgeries, increased muscle tension makes it harder for the surgeon to expose the site of surgery and work within the incision. Neuromuscular blockade (NMB) drugs such as Vecuronium bind to neurotransmitter (acetyl choline) receptors at the neuromuscular junction, blocking their action and producing muscle ... | Does Deep Neuromuscular Blockade Improve Operating Conditions During Total Hip Replacements? | [
{
"description": "Vecuronium will be administered to achieve and maintain 1 to 2 TOF contractions.",
"name": "Vecuronium 0.1 mg/kg",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"vecuronium bromide"
],
"type": "Drug"
},
{
"description": "Vecuronium wil... | [
{
"design_group_description": "Intubating dose of Vecuronium 0.1 mg/kg (IBW) and re-dosing with 0.0125 to 0.05 mg/kg as needed to achieve and maintain 1 to 2 train-of-four (TOF) contractions. Redosing in this manner is a current clinical practice.",
"design_group_title": "Moderate Neuromuscular Blockade (NM... | [
"Arthropathy of Hip"
] | [
"MaineHealth"
] | [
"MaineHealth",
"Spectrum Medical Group Ltd."
] | [
[
{
"name": "维库溴铵",
"lang": "CN"
},
{
"name": "Vecuronium Bromide",
"lang": "EN"
},
{
"name": "ベクロニウム臭化物",
"lang": "JP"
}
]
] | null |
NCT01013532 | [
{
"id_field": "org_study_id",
"id_value": [
"PICASSO"
]
},
{
"id_field": "acronym",
"id_value": [
"PICASSO"
]
}
] | https://clinicaltrials.gov/study/NCT01013532 | PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage | Through this study, the investigators are to prove that Cilostazol effectively prevent cardiovascular events in ischemic stroke patients with high risk of cerebral hemorrhage, along with no significant increase in the risk of occurrence of hemorrhagic side effects.<br/>The primary hypothesis of this study is; Cilostazo... | A Multicenter, Double Blind, Factorial Design, Phase IV Trial to Compare the Efficacy and Safety of Cilostazol Long-term Treatment With Aspirin in Ischemic Stroke Patients With High Risk of Cerebral Hemorrhage for the Prevention of Cerebral Hemorrhage and Cardiovascular Events and to Compare the Preventive Effect of Pr... | [
{
"description": "Cilostazol 100mg bid",
"name": "Cilostazol",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Pletaal produced by Korea Otsuka Pharmaceutical company"
],
"type": "Drug"
},
{
"description": "Probucol 250mg bid",
"name": "Probucol",
... | [
{
"design_group_description": "100mg cilostazol bid plus probucol plus placebo of aspirin",
"design_group_title": "Cilostazol+ Probucol",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_de... | [
"Brain Ischemia",
"Intracranial Hemorrhages"
] | [
"Asan Medical Center"
] | [
"Korea Otsuka Pharmaceutical Co., Ltd."
] | [
[
{
"name": "普罗布考",
"lang": "CN"
},
{
"name": "Probucol",
"lang": "EN"
},
{
"name": "プロブコール",
"lang": "JP"
}
],
[
{
"name": "西洛他唑",
"lang": "CN"
},
{
"name": "Cilostazol",
"lang": "EN"
},
{
"name": "シロス... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "e4552d8d0aa29a42225e802a0885e482",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "PICASSO"
}
] |
NCT03427892 | [
{
"id_field": "org_study_id",
"id_value": [
"102016-048"
]
}
] | https://clinicaltrials.gov/study/NCT03427892 | Brexpiprazole for Bipolar Depression | The investigators will conduct an 8-week, non-randomized, open-label study of brexpiprazole in 20 persons with bipolar I or II disorder, depressed mood state. Primary aim will be to assess if brexpiprazole is associated with a reduction in depressive symptom severity using the Montgomery-Asberg Depression Rating Scale ... | Brexpiprazole for Bipolar Depression | [
{
"description": "Brexpiprazole is an atypical antipsychotic drug that is used to treat mental/mood disorders.",
"name": "Brexpiprazole",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Rexulti"
],
"type": "Drug"
}
] | [
{
"design_group_description": "Brexipiprazole will be taken orally beginning at 0.5 mg/day with an increase to 1 mg/day at week 1 and 2 mg/day at week 2. If reduction in mood symptoms does not occur, the dose will increase to 3 mg/day and 4 mg/day.",
"design_group_title": "Brexpiprazole",
"design_group_... | [
"Bipolar Depression"
] | [
"The University of Texas Southwestern Medical Center"
] | [
"Otsuka America Pharmaceutical, Inc."
] | [
[
{
"name": "布瑞哌唑",
"lang": "CN"
},
{
"name": "Brexpiprazole",
"lang": "EN"
},
{
"name": "ブレクスピプラゾール",
"lang": "JP"
}
]
] | null |
NCT03650543 | [
{
"id_field": "org_study_id",
"id_value": [
"00004554"
]
},
{
"id_domain": "Pontificia Universidad Javeriana",
"id_field": "secondary_id",
"id_type": "Other Grant/Funding Number",
"id_value": [
"00004554"
]
},
{
"id_domain": "Pontificia Universidad Javeriana",... | https://clinicaltrials.gov/study/NCT03650543 | Effect of the CYP2C19 Polymorphism in Helicobacter Pylori Eradication | Background: Triple therapy efficacy against Helicobacter pylori is low worldwide, thus alternatives must be sought to improve eradication. Aim: To determine CYP2C19 genetic polymorphism effect on H. pylori eradication.<br/>Methods: A randomized single blinded clinical trial including 133 patients was carried-out. H. py... | Effect of the CYP2C19 Polymorphism in Helicobacter Pylori Eradication | [
{
"description": "Patients in this received triple standard therapy for eradication of H.pylori with standard doses of proton pump inhibitor (omeprazole), in combination with amoxicillin and clarithromycin in absence of antibiotic resistance.",
"name": "amoxicillin clarithromycin omeprazole 1",
"normali... | [
{
"design_group_description": "This group received triple standard therapy with standard doses of omeprazole. 20 mg \"omeprazole\" before breakfast and before dinner. 500 mg \"clarithromycin\" after breakfast and after dinner and 1 g \"amoxicillin\" after breakfast and after dinner for 10 days.",
"design_gr... | [
"CYP2C19 Polymorphism",
"H.Pylori Infection",
"Therapy"
] | [
"Pontificia Universidad Javeriana"
] | [
"Universidad Nacional de Colombia"
] | [
[
{
"name": "马来酸溴苯那敏/盐酸去氧肾上腺素",
"lang": "CN"
},
{
"name": "Brompheniramine Maleate/Phenylephrine Hydrochloride",
"lang": "EN"
}
]
] | null |
NCT03921294 | [
{
"id_field": "org_study_id",
"id_value": [
"RO-IIS-2018-10581"
]
}
] | https://clinicaltrials.gov/study/NCT03921294 | HemLibra Prophylaxis in Patients With Hemophilic Pseudotumor | This is a single arm, phase 4, prospective, open-label, United States single-center study to assess the hemostatic efficacy and safety of Hemlibra (emicizumab) for hemostatic control of hemophilia A patients (baseline FVIII level <40%) with and without inhibitors with hemophilic pseudotumors; secondary outcomes will as... | Prospective, Single-arm, Open-label Use of Hemlibra (Emicizumab) to Treat Hemophilic Pseudotumor | [
{
"description": "bispecific monoclonal antibody binding to activated Factor IX and Factor X",
"name": "Emicizumab",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"HemLibra"
],
"type": "Drug"
}
] | [
{
"design_group_description": "Patients with hemophilic pseudotumor will be treated with prophylactic emicizumab and assessed for improvement.",
"design_group_title": "Single Arm",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"interv... | [
"Haemophilic Pseudotumour"
] | [
"Indiana Hemophilia & Thrombosis Center, Inc."
] | [
"Genentech, Inc."
] | [
[
{
"name": "艾美赛珠单抗",
"lang": "CN"
},
{
"name": "Emicizumab",
"lang": "EN"
},
{
"name": "エミシズマブ（遺伝子組換え）",
"lang": "JP"
}
]
] | null |
NCT02444507 | [
{
"id_field": "org_study_id",
"id_value": [
"YSP RFH3002-01"
]
}
] | https://clinicaltrials.gov/study/NCT02444507 | A Pharmacokinetic Study to Evaluate the Bioequivalence of a Test Formulation Compared to an Equivalent Dose of a Reference Drug Product | To assess the bioequivalence of esomeprazole of the TEST product vs. the REFERENCE product in healthy volunteers who reside in Taiwan. | A Randomized, Two-Way Crossover, Single-Dose Pharmacokinetic Study to Evaluate the Bioequivalence of a Test Formulation Compared to an Equivalent Dose of a Reference Drug Product (Nexium Powder for Injection and Infusion 40 mg) in Healthy Adult Subjects | [
{
"description": "Reference Drug, Active substance: Esomeprazole 40 mg, Each single dose of esomeprazole 40 mg will be administrated as intravenous infusion over 30 minutes.",
"name": "Nexium powder for injection and infusion 40 mg",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Dr... | [
{
"design_group_description": "Name: Nexium powder for injection and infusion 40 mg, Active substance: Esomeprazole 40 mg, Each single dose of esomeprazole 40 mg will be administrated as intravenous infusion over 30 minutes.",
"design_group_title": "Reference Drug: Nexium",
"design_group_type": "Active ... | [
"Healthy Adult Subjects"
] | [
"isRed Pharma & Biotech Research Co.,Ltd."
] | [
"Yung Shin Pharmaceutical Industrial Co., Ltd."
] | [
[
{
"name": "埃索美拉唑锶",
"lang": "CN"
},
{
"name": "Esomeprazole Strontium",
"lang": "EN"
}
],
[
{
"name": "埃索美拉唑镁",
"lang": "CN"
},
{
"name": "Esomeprazole Magnesium",
"lang": "EN"
},
{
"name": "エソメプラゾールマグネシウム水和物",
"la... | null |
NCT02222246 | [
{
"id_field": "org_study_id",
"id_value": [
"Pro00054047"
]
},
{
"id_domain": "NHLBI",
"id_field": "secondary_id",
"id_type": "Other Grant/Funding Number",
"id_value": [
"R34 RHL121224A"
]
}
] | https://clinicaltrials.gov/study/NCT02222246 | Comparing Acute Pain Management Protocols for Patients With Sickle Cell Disease | The goal of this pilot study is to improve emergency department (ED) pain management for adults with sickle cell disease. Sickle cell disease (SCD) is the most common genetic disorder in the United States, and occurs primarily among African Americans. Management of painful episodes associated with SCD, referred to as v... | Comparing Acute Pain Management Protocols for Patients With Sickle Cell Disease | [
{
"description": "Standardized analgesic management using a SCD specific standard protocol based on NHBLI guidelines (initial opioid dose weight-based).",
"name": "Hydromorphone (Standardized, weight-based dosing)",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Dilaud... | [
{
"design_group_description": "A patient-specific analgesic protocol for use in the ED to manage VOC crises. Following randomization, a patient's healthcare team will develop a specific analgesic protocol for use during future ED visits for VOC occurring during the study period (up to 5 visits). Treatment proto... | [
"Sickle Cell Disease"
] | [
"Duke University"
] | [
"National Heart, Lung & Blood Institute",
"University of Cincinnati (Ohio)",
"The Mount Sinai Hospital",
"National Institutes of Health"
] | [
[
{
"name": "盐酸氢吗啡酮",
"lang": "CN"
},
{
"name": "Hydromorphone Hydrochloride",
"lang": "EN"
},
{
"name": "ヒドロモルフォン塩酸塩",
"lang": "JP"
}
],
[
{
"name": "硫酸吗啡",
"lang": "CN"
},
{
"name": "Morphine Sulfate",
"lang": "EN"... | null |
NCT03370536 | [
{
"id_field": "org_study_id",
"id_value": [
"GCO 40-5004"
]
}
] | https://clinicaltrials.gov/study/NCT03370536 | ECGi Ibutilide: Effect of Ibutilide on AF Source Location and Organization | This is a prospective, multi-center, non-randomized, un-blinded, observational trial. | Panoramic ECGi to Guide Ablation of Non-Paroxysmal AF: Effect of Ibutilide on AF Source Location and Organization | [
{
"description": "The CardioInsight mapping system is a noninvasive, single beat cardiac arrhythmia mapping system that provides 3D electroanatomic maps of the heart.",
"name": "CardioInsight ECGI Mapping System",
"normalized_type": "63bce838d71c4229808b289e8cf3172d",
"other_name": [
"ECGi map... | [
{
"design_group_description": "Patients with AF and planned to undergo first catheter procedure",
"design_group_title": "Patients with AF",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_... | [
"Atrial Fibrillation",
"Persistent Atrial Fibrillation"
] | [
"Icahn School of Medicine at Mount Sinai"
] | [
"Medtronic Plc"
] | [
[
{
"name": "富马酸伊布利特",
"lang": "CN"
},
{
"name": "Ibutilide Fumarate",
"lang": "EN"
}
]
] | null |
NCT00991510 | [
{
"id_field": "org_study_id",
"id_value": [
"116B8"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2009-010562-31"
]
}
] | https://clinicaltrials.gov/study/NCT00991510 | Comparative Bioavailability of Myfenax® and CellCept® in Kidney Transplant Patients | The purpose of the study is to further investigate how much of the drug substance "mycophenolate mofetil" can be found in the blood of patients with kidney or renal transplants when treated with Myfenax® or CellCept®. Additionally, the safety and side effects of the two products will be compared. All information alread... | Comparative Bioavailability of Myfenax® (Teva) and CellCept® (Roche) in Stable Patients After Renal Transplantation | [
{
"description": "Each participant received at least 500 mg orally, twice daily (morning and evening) during those study periods labeled as 'T' (test drug). Participants receive the dose equivalent to the pre-study dose (within the recommended therapeutic range) of mycophenolate mofetil.",
"name": "mycophen... | [
{
"design_group_description": "The reference product was CellCept® and test product was Myfenax®. In period I, participants received CellCept on Days 1-14. In period II, participants crossed-over to receive Myfenax on Days 15-28. In period III, participants received Myfenax until the end of the study (Days 29-1... | [
"Stable Renal Transplant Recipients"
] | [
"Teva Branded Pharmaceutical Products R&D LLC"
] | [
"PAREXEL International Corp."
] | [
[
{
"name": "吗替麦考酚酯",
"lang": "CN"
},
{
"name": "Mycophenolate Mofetil",
"lang": "EN"
},
{
"name": "ミコフェノール酸 モフェチル",
"lang": "JP"
}
]
] | null |
NCT05021731 | [
{
"id_field": "org_study_id",
"id_value": [
"PI21/00444"
]
}
] | https://clinicaltrials.gov/study/NCT05021731 | Short-course Rifamycin-based Regimens for Latent Tuberculosis in Patients With End-stage Kidney Disease | Objective To determine if treatment completion with a 4-month rifampin (4R) or 3-month rifapentine (P) + isoniazid (H) weekly for 12 weeks (3HP) regimens is better than with a 3-month (3HR) regimen for treatment of latent tuberculosis (TB) infection (LTBI) in patients with end stage kidney disease.<br/>Methods Design: ... | Comparison of 3-month Once-weekly Isoniazid Plus Rifapentine, 4-month Daily Rifampicin, and 3-month Daily Isoniazid Plus Rifampicin for the Treatment Latent Tuberculosis in Patients With End-stage Kidney Disease: A Randomised Clinical Trial | [
{
"description": "Administration of rifampicin plus isoniazid for latent tuberculosis",
"name": "Rifampicin plus Isoniazid",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Administration of rifapentine plus isoniazid for latent tuberculosis",
"... | [
{
"design_group_description": "Daily isoniazid 300 mg plus rifampicin 600 mg for three months",
"design_group_title": "3-month Isoniazid plus Rifampicin",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
... | [
"Latent Tuberculosis",
"Kidney Failure"
] | [
"Bellvitge University Hospital"
] | [
"Institut d'Investigació Biomèdica de Bellvitge",
"Instituto De SAlud Carlos Iii De Madrid"
] | [
[
{
"name": "利福喷丁",
"lang": "CN"
},
{
"name": "Rifapentine",
"lang": "EN"
}
],
[
{
"name": "利福平",
"lang": "CN"
},
{
"name": "Rifampin",
"lang": "EN"
},
{
"name": "リファンピシン",
"lang": "JP"
}
],
[
{
"na... | null |
NCT05311930 | [
{
"id_field": "org_study_id",
"id_value": [
"TPO-RAs-old patients"
]
}
] | https://clinicaltrials.gov/study/NCT05311930 | Efficacy and Safety of TPO Receptor Agonists in the Treatment of Elderly ITP Patients | Elderly ITP patients have many underlying diseases, hormone contraindications and many adverse reactions during the use of hormones. TPO-RAs are oral small-molecule non-peptide drugs. Retrospective studies have shown that they have good efficacy and high safety in elderly patients. Therefore, this study is a prospectiv... | Efficacy and Safety of TPO Receptor Agonists as First-line Drugs in the Treatment of Newly Diagnosed Elderly ITP Patients in China-an Open Label Study | [
{
"description": "After the subjects signed the informed consent and passed the screening, they entered the treatment period and received a starting dose of 2.5 mg/d of Hytrombopag. During the treatment process, the clinician adjusted the drug dose according to the patient's own conditions. The maximum drug dos... | [
{
"design_group_description": "After the subjects signed the informed consent and passed the screening, they entered the treatment period and received a starting dose of 2.5 mg/d of Hetrabopag. During the treatment process, the clinician adjusted the drug dose according to the patient's own conditions. The maxi... | [
"Primary Immune Thrombocytopenia"
] | [
"Wuhan Xiehe Hospital Tower"
] | [
"Jiangsu Hengrui Pharmaceuticals Co., Ltd."
] | [
[
{
"name": "海曲泊帕乙醇胺",
"lang": "CN"
},
{
"name": "Herombopag Olamine",
"lang": "EN"
}
]
] | null |
NCT07078786 | [
{
"id_field": "org_study_id",
"id_value": [
"1080/IREF/RMU/2024"
]
}
] | https://clinicaltrials.gov/study/NCT07078786 | Effect of Pre-delivery Dexamethasone in Comparison With Betamethasone on Fetal Heart Trace | As baby grows inside the womb of mother, heart and other organs develop. The heart activity can be recorded by placing a transducer on the belly of mother. The tracing obtain provides information about heart rate, any increase or decrease in heart rate and how much it varies with time. Variation in heart rate along wit... | Comparison of Effect of Antenatal Dexamethasone Versus Betamethasone on Antepartum Cardiactocography | [
{
"description": "Intramuscular injection of Betamethasone 12mg will be administered on 2 consecutive days",
"name": "Betamethason Sodium Phosphate",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "two doses of 12mg of IM Dexamethasone given 24 hour... | [
{
"design_group_description": "Intramuscular injection of Betamethasone 12mg will be administered on 2 consecutive days",
"design_group_title": "Group Betamethasone",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
... | [
"Cardiotocography",
"Steroids"
] | [
"Rawalpindi Medical College"
] | [
"Rawalpindi Medical College"
] | [
[
{
"name": "磷酸钠倍他米松",
"lang": "CN"
},
{
"name": "Betamethasone Sodium Phosphate",
"lang": "EN"
},
{
"name": "ベタメタゾンリン酸エステルナトリウム",
"lang": "JP"
}
]
] | null |
NCT03382106 | [
{
"id_field": "org_study_id",
"id_value": [
"201706713"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"R01HL130883"
]
}
] | https://clinicaltrials.gov/study/NCT03382106 | Smoking Cessation and Functional CT Assessment | The investigators will study the effect of pulmonary arterial vasodilation to see if it eliminates indices of persistent lung injury in smokers that are susceptible to emphysema. | Smoking Cessation and Functional CT Assessment of Pulmonary Arterial Dysfunction in Smoking Associated Emphysema | [
{
"description": "Sildenafil, 20mg three times daily for 3 month period.",
"name": "Sildenafil 20 MG",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Experimental: Non-Smokers Group 1",
"Experimental: Smoking Cessation Group 1"
],
"type": "Drug"
},
{
... | [
{
"design_group_description": "80 normal smokers will be recruited (defined by Pulmonary Function Tests, questionnaires and interviews), between the ages of 21 and 65 will be studied to assess inflammation and heterogeneity of Perfused Blood Volume prior to and following a 3 month smoking cessation program. In ... | [
"Emphysema"
] | [
"University of Iowa"
] | [
"National Heart, Lung & Blood Institute",
"National Institutes of Health"
] | [
[
{
"name": "枸橼酸西地那非",
"lang": "CN"
},
{
"name": "Sildenaifl Citrate",
"lang": "EN"
},
{
"name": "シルデナフィルクエン酸塩",
"lang": "JP"
}
]
] | null |
NCT01822418 | [
{
"id_field": "org_study_id",
"id_value": [
"01112012"
]
},
{
"id_field": "acronym",
"id_value": [
"AGOPSYCH"
]
}
] | https://clinicaltrials.gov/study/NCT01822418 | Agomelatine Treatment of Depression in Schizophrenia (AGOPSYCH) | Major depressive episodes (MDEs) occur frequently during the course of psychotic disorders, and several antidepressive agents have been successfully applied. The new melatonergic antidepressant agomelatine (AGO) appears promising for the treatment of MDEs in schizophrenia for several reasons. The investigators plan to ... | Agomelatine Treatment of Major Depressive Episodes in the Course of Schizophrenic Psychoses (AGOPSYCH) | [
{
"description": "Augmentation of antipsychotic therapy with 25 to 50 mg agomelatine as a single oral dosage per day",
"name": "agomelatine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Valdoxan"
],
"type": "Drug"
}
] | [
{
"design_group_description": "Open-label treatment with agomelatine 25 mg/day (or 50 mg/day after week 3).",
"design_group_title": "Treatment",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"interven... | [
"Schizophrenia",
"Schizoaffective Disorder",
"Delusional Disorder"
] | [
"Zentralinstitut für Seelische Gesundheit"
] | [
"Servier Pharmaceuticals LLC"
] | [
[
{
"name": "阿戈美拉汀",
"lang": "CN"
},
{
"name": "Agomelatine",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "AGOPSYCH"
}
] |
NCT07036991 | [
{
"id_field": "org_study_id",
"id_value": [
"TRIP-CAS"
]
},
{
"id_field": "acronym",
"id_value": [
"TRIP-CAS"
]
}
] | https://clinicaltrials.gov/study/NCT07036991 | Clinical Trial of PCSK9 Inhibitor and Statin Treatment for Carotid Artery Stenosis | A prospective, multicenter, randomized controlled, open-label, blinded outcome evaluation (PROBE) trial. | A Randomized Clinical TRial on Inhibitor of PCSK9 and Statin Treatment for Carotid Artery Stenosis (TRIP-CAS) | [
{
"description": "PCSK9 inhibitor (biweekly injections) + rosuvastatin/atorvastatin ± ezetimibe",
"name": "Evolocumab (biweekly injections) + Rosuvastatin/Atorvastatin ± Ezetimibe",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Rosuvastatin/atorva... | [
{
"design_group_description": "PCSK9 inhibitor (biweekly injections) + rosuvastatin/atorvastatin ± ezetimibe, initiated on randomization day",
"design_group_title": "PCSK9 Inhibitor + Statin ± Ezetimibe Group",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b3544... | [
"Carotid Artery Stenosis"
] | [
"Changhai Hospital of Shanghai"
] | [
"The First Affiliated Hospital of Soochow University"
] | [
[
{
"name": "阿托伐他汀钙",
"lang": "CN"
},
{
"name": "Atorvastatin Calcium",
"lang": "EN"
},
{
"name": "アトルバスタチンカルシウム水和物",
"lang": "JP"
}
],
[
{
"name": "瑞舒伐他汀钙",
"lang": "CN"
},
{
"name": "Rosuvastatin Calcium",
"lang": ... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "TRIP-CAS"
}
] |
NCT00625339 | [
{
"id_field": "org_study_id",
"id_value": [
"4-2007-0367"
]
}
] | https://clinicaltrials.gov/study/NCT00625339 | Continuing Lamivudine Versus Switching to Entecavir in Patients Who Achieved Undetectable HBV DNA | This is a randomized, open-labelled, prospective 96-week study comparing the antiviral efficacy and safety of switching to entecavir 0.5mg QD from lamivudine versus maintaining lamivudine 100mg QD treatment in CHB patients currently receiving lamivudine monotherapy. | Randomized, Open-Labeled Study Evaluating the Antiviral Efficacy, Safety, and Tolerability of Continuing Lamivudine Therapy or Switching to Entecavir in Subjects With Chronic Hepatitis B Who Achieved Undetectable HBV DNA | [
{
"description": "entecavir 0.5 mg QD",
"name": "Entecavir",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Baraclude 0.5mg"
],
"type": "Drug"
},
{
"description": "lamivudine 100 mg QD",
"name": "Lamivudine",
"normalized_type": "3d1aa88261d64c03... | [
{
"design_group_description": "entecavir 0.5 mg QD",
"design_group_title": "A",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "entecavir 0.5 mg QD",
"intervention_n... | [
"Hepatitis B, Chronic"
] | [
"Yonsei University"
] | [
"Pusan National University Hospital"
] | [
[
{
"name": "恩替卡韦",
"lang": "CN"
},
{
"name": "Entecavir",
"lang": "EN"
},
{
"name": "エンテカビル水和物",
"lang": "JP"
}
]
] | null |
NCT04094727 | [
{
"id_field": "org_study_id",
"id_value": [
"Malaria HRP in Namibia"
]
}
] | https://clinicaltrials.gov/study/NCT04094727 | Malaria High-Risk Populations in Namibia | This study aims to determine the effectiveness, cost-effectiveness, acceptability, and feasibility of targeted delivery of a package of malaria interventions for improving effective coverage and reducing Plasmodium falciparum malaria transmission among malaria high-risk populations in Northern Namibia. Previous researc... | Targeting Malaria High-risk Populations With Tailored Intervention Packages: A Study to Assess Feasibility and Effectiveness in Northern Namibia | [
{
"description": "All eligible HRPs will be presumptively treated with artemether-lumefantrine (AL) at two timepoints, separated by at least one month. All individuals who have provided informed consent, meet eligibility criteria, are not pregnant or breastfeeding, and who do not have symptoms associated with s... | [
{
"design_group_description": "For all eligible HRPs in intervention areas, after obtaining informed consent, presumptive treatment for malaria will be carried out using artemether-lumefantrine (AL) at two time points.<br/>Enhanced vector control activities will include: (1) a mop up indoor residual spraying (I... | [
"Malaria"
] | [
"The University of California, San Francisco"
] | [
"The University of Texas Southwestern Medical Center",
"University of Namibia",
"University of Notre Dame",
"Namibia Ministry of Health & Social Services",
"London School of Hygiene & Tropical Medicine"
] | [
[
{
"name": "复方蒿甲醚",
"lang": "CN"
},
{
"name": "Artemether/Lumefantrine",
"lang": "EN"
},
{
"name": "アルテメテル/ルメファントリン",
"lang": "JP"
}
]
] | null |
NCT02498977 | [
{
"id_field": "org_study_id",
"id_value": [
"ASF/001-01"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2014-004557-14"
]
},
{
"id_field": "acronym",
"id_value": [
"LIFT"
]
}
] | https://clinicaltrials.gov/study/NCT02498977 | Liver Immunosuppression Free Trial | LIFT is prospective randomised marker-based trial to assess the clinical utility and safety of biomarker-guided immunosuppression withdrawal in liver transplantation. 'LIFT' aims to validate a biomarker test of operational tolerance to stratify liver transplant recipients before withdrawing immunosuppressive medication... | Prospective Randomised Marker-based Trial to Assess the Clinical Utility and Safety of Biomarker-guided Immunosuppression Withdrawal in Liver Transplantation | [
{
"description": "Real time polymerase chain reaction (PCR) gene expression measurement",
"name": "Biomarker",
"normalized_type": "288887f0545745558ff1ab1c85757552",
"type": "Genetic"
},
{
"description": "Immunosuppression drugs as per protocol",
"name": "Tacrolimus, cyclosporine and/or ... | [
{
"design_group_description": "All participants satisfying clinical criteria will be weaned off immunosuppression drugs irrespective of biomarker result.",
"design_group_title": "Arm A (weaning)",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e7... | [
"Transplantation, Liver"
] | [
"King's College London"
] | [
"King's College Hospital NHS Foundation Trust"
] | [
[
{
"name": "环孢素",
"lang": "CN"
},
{
"name": "Cyclosporine",
"lang": "EN"
},
{
"name": "シクロスポリン",
"lang": "JP"
}
],
[
{
"name": "他克莫司",
"lang": "CN"
},
{
"name": "Tacrolimus",
"lang": "EN"
},
{
"name": ... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "LIFT"
}
] |
NCT06705764 | [
{
"id_field": "org_study_id",
"id_value": [
"ESR-22-22102"
]
},
{
"id_field": "acronym",
"id_value": [
"TERAA"
]
},
{
"id_field": "secondary_id",
"id_value": [
"ESR-22-22102"
]
}
] | https://clinicaltrials.gov/study/NCT06705764 | Tezepelumab in the Treatment of Emergency Room Asthma in Adults (TERAA) | Adults with severe asthma may have sudden worsening shortness of breath that results in their going to Emergency Department for urgent care. Emergency Room visits for asthma management across Alberta have been reviewed and it has been found that adults frequently need to return for repeated worsening. This is a large d... | Tezepelumab in the Treatment of Emergency Room Asthma in Adults (TERAA): A Phase 4 Double-Blinded, Parallel-Group, Randomized Control Trial With an Open Label Extension | [
{
"description": "Tezepelumab 210 mg (1.91 ml) subcutaneous every 4 weeks. Randomized Control Trial 90 days with Tezepelumab/ Matching Placebo dosing on Day 0, Day 30 and Day 60.<br/>Open-label extension study from Day 90 to Day 180 with Tezepelumab dosing at Day 90",
"name": "Tezepelumab",
"normalized_... | [
{
"design_group_description": "Tezepelumab 210 mg S/Q Q4W",
"design_group_title": "Tezepelumab",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"intervention_description": "Tezepelumab 210 mg (1.9... | [
"Severe Asthma"
] | [
"University of Alberta"
] | [
"AstraZeneca PLC"
] | [
[
{
"name": "特泽利尤单抗",
"lang": "CN"
},
{
"name": "Tezepelumab",
"lang": "EN"
},
{
"name": "テゼペルマブ (遺伝子組換え)",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "TERAA"
}
] |
NCT04101890 | [
{
"id_field": "org_study_id",
"id_value": [
"12239"
]
}
] | https://clinicaltrials.gov/study/NCT04101890 | The Healthy Baby Bottoms Study | Diaper dermatitis is one of the most common dermatologic diseases affecting infants and children. The incidence is highest among those 9-12 months old and it has been reported to affect 7-50% of infants in the US. It is caused by skin exposure to a combination of several factors including: excessive moisture, topical i... | The Healthy Baby Bottoms Study: A Trial of Theraworx Foam Formulation for the Prevention and Treatment of Diaper Dermatitis | [
{
"description": "Theraworx foam formulation to be used as a preventive and treatment agent for diaper rashes",
"name": "Diaper care with Theraworx",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "Participants will be given a 4 week supply of Theraworx Spray Foam, an FDA-registered OTC drug (NDC 61594-000), to apply a thin layer to their infant's entire diaper area with every diaper change (2-4 foam pumps or 4-6 sprays depending on the infant's size) for 4 weeks.",
"des... | [
"Diaper Dermatitis"
] | [
"Children's National Research Institute"
] | [
"AH Liquidation, Inc."
] | [
[
{
"name": "尿囊素",
"lang": "CN"
},
{
"name": "Allantoin",
"lang": "EN"
}
]
] | null |
NCT00018759 | [
{
"id_field": "org_study_id",
"id_value": [
"MHBS-023-00S"
]
}
] | https://clinicaltrials.gov/study/NCT00018759 | Treatment Effects on Platelet Calcium in Hypertensive and Depressed Patients | This study aims to determine if treatment with an SSRI antidepressant medication, paroxetine, is associated with cellular calcium response to serotonin, platelet serotonin receptors, and improvement in mood in depressed patients with or without hypertension. It is hypothesized that platelets of hypertensive patients wi... | Treatment Effects on Platelet Calcium in Hypertensive and Depressed Patients | [
{
"name": "paroxetine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
},
{
"name": "ongoing psychological screening",
"normalized_type": "f9cf04e7d3da41f2ae5e11bc777942f7",
"type": "Behavioral"
}
] | null | [
"Depression",
"Hypertension"
] | [
"US Department of Veterans Affairs (District of Columbia)"
] | [
"Smithkline Beecham Plc"
] | [
[
{
"name": "盐酸帕罗西汀",
"lang": "CN"
},
{
"name": "Paroxetine Hydrochloride",
"lang": "EN"
},
{
"name": "パロキセチン塩酸塩水和物",
"lang": "JP"
}
]
] | null |
NCT02232971 | [
{
"id_field": "org_study_id",
"id_value": [
"GluST1_2014"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2014-002267-15"
]
},
{
"id_domain": "The National Committee on Health Research Ethics",
"id_field": "secondary_id",
"id... | https://clinicaltrials.gov/study/NCT02232971 | Treatment of Low Blood Sugar With Glucagon Among Patients With Type 1 Diabetes | Background: Patients with type 1 diabetes (T1D) need a lifelong supply of external insulin and are advised to aim for near-normalization of blood glucose levels through intensive insulin therapy. We propose a new approach for achieving treatment goals in T1D: the combined use of insulin and glucagon, i.e. dual-hormone ... | Treatment of Hypoglycemia With Glucagon Among Patients With Type 1 Diabetes Mellitus | [
{
"description": "Glucagon is given in three different doses according to three research days.",
"name": "Glucagon",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"2880 Bagsværd",
"Disp. no. 2514",
"GlucaGen (r)",
"Novo Allé",
"Novo Nordisk A/S"... | [
{
"design_group_description": "Isotonic Saline",
"design_group_title": "Placebo",
"design_group_type": "Placebo Comparator",
"design_group_type_normalized_id": "20d1ebb7d90a3d9b81daa54f73163ecb",
"intervention": [
{
"intervention_description": "Placebo",
"intervention_name"... | [
"Diabetes Mellitus, Type 1"
] | [
"Hvidovre University Hospital"
] | [
"Novo Nordisk Foundation",
"University of Copenhagen"
] | [
[
{
"name": "Glucagon(Xeris Pharmaceuticals, Inc.)",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "GluST1"
}
] |
NCT02685072 | [
{
"id_field": "org_study_id",
"id_value": [
"1504015618"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"R21CA198187"
]
},
{
"id_field": "acronym",
"id_value": [
"PANS"
]
}
] | https://clinicaltrials.gov/study/NCT02685072 | Progesterone Augmentation of Nicotine Replacement Therapy Study | This will be a double-blind, placebo-controlled, pilot, randomized clinical trial. A total of 50 women who smoke and have regular menstrual cycles will be randomized to either progesterone (200 mgs BID) + Transdermal Nicotine Patch (TNP) or placebo + TNP for 8 weeks. TNP will be tapered after 4-6 weeks. Progesterone or... | Progesterone Augmentation of Nicotine Replacement Therapy Study | [
{
"description": "Transdermal Nicotine Patch (TNP) + Progesterone",
"name": "Progesterone (200 mgs BID)",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Prometrium"
],
"type": "Drug"
},
{
"description": "TNP + Placebo",
"name": "Placebo",
"norma... | [
{
"design_group_description": "Transdermal Nicotine Patch + Progesterone (200 mgs BID)",
"design_group_title": "TNP + Progesterone",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_descrip... | [
"Smoking Cessation"
] | [
"Yale University"
] | [
"National Cancer Institute"
] | [
[
{
"name": "黄体酮",
"lang": "CN"
},
{
"name": "Progesterone",
"lang": "EN"
},
{
"name": "プロゲステロン",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "a28022439ae550e228a38222d405e88a",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "PANS"
}
] |
NCT00734968 | [
{
"id_field": "org_study_id",
"id_value": [
"1108717"
]
}
] | https://clinicaltrials.gov/study/NCT00734968 | Does Treatment With Macrobid Reduce Urinary Tract Infections in Patients Receiving a Sub-Urethral Sling for Incontinence | This project will determine whether post-operative prophylaxis with macrobid will decrease the incidence of postoperative urinary tract infection in women receiving sub-urethral slings for the treatment of urinary incontinence. | Does Prophylaxis With Macrobid Reduce the Incidence of Urinary Tract Infection in Patients Who Receive a Sub-Urethral Sling for the Treatment of Stress Urinary Incontinence: Randomized, Double Blinded Placebo Controlled Clinical Trial | [
{
"description": "Nitrofurantoin 100mg PO BID for 3 days post operatively following the placement of a sub-urethral sling for the treatment of stress urinary incontinence",
"name": "Nitrofurantoin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Macrobid"
],
"t... | [
{
"design_group_description": "Patients randomly assigned to be treated with nitrofurantoin 100mg PO BID x 3 days post-operatively",
"design_group_title": "Treatment",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
... | [
"Stress Incontinence"
] | [
"University of Missouri"
] | [
"Texas A&M University"
] | [
[
{
"name": "呋喃妥因",
"lang": "CN"
},
{
"name": "Nitrofurantoin",
"lang": "EN"
}
]
] | null |
NCT04576377 | [
{
"id_field": "org_study_id",
"id_value": [
"BJC033"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"1U01AI153700"
]
},
{
"id_field": "acronym",
"id_value": [
"DRIVE"
]
}
] | https://clinicaltrials.gov/study/NCT04576377 | Dynamics of the Immune Responses to Repeat Influenza Vaccination Exposures | The aims of this vaccine trial are: (1) to measure humoral and selected cellular immune responses to repeated influenza vaccination with Flublok, including these responses' associations with age, birth year, and prior vaccination history; (2) to identify the characteristics of study participants who are vaccinated but ... | The Dynamics of the Immune Responses to Repeat Influenza Vaccination Exposures (DRIVE) Study - a Randomized Controlled Trial | [
{
"description": "Recombinant HA quadrivalent influenza vaccine (0.5mL Flublok®, Sanofi Pasteur) containing 180μg antigen, 45μg for each influenza strain included.",
"name": "FluBlok",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
},
{
"description": "0.5mL sali... | [
{
"design_group_title": "Influenza vaccination",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Recombinant HA quadrivalent influenza vaccine (0.5mL Flublok®, Sanofi Pasteur) c... | [
"Influenza, Human"
] | [
"The University of Hong Kong"
] | [
"The University of Chicago",
"National Institute of Allergy & Infectious Diseases"
] | [
[
{
"name": "重组四价流感疫苗(Protein Sciences)",
"lang": "CN"
},
{
"name": "Recombinant Influenza vaccine quadrivalent(Protein Sciences Corp.)",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "DRIVE"
}
] |
NCT01272414 | [
{
"id_field": "org_study_id",
"id_value": [
"10-0261-A"
]
}
] | https://clinicaltrials.gov/study/NCT01272414 | Use of Botox in the Management of Thyroid Related Upper Eyelid Retraction | Currently there are few therapeutic options for the treatment of lid retraction secondary to thyroid orbitopathy (TO) during the active stages of the disease. BoTox injection is capable of creating a ptosis, that in the setting of TO can return the upper lid to a more physiologic position, thus improving cosmesis, corn... | null | [
{
"description": "2-12 units in weekly 2u doses to effect",
"name": "Botulinum Toxin Type A",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"BoTox"
],
"type": "Drug"
},
{
"description": "Injection of 0.4cc 0.9% normal saline",
"name": "Saline inject... | [
{
"design_group_description": "Subjects receive BoTox injection to levator complex",
"design_group_title": "BoTox Treatment",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": ... | [
"Graves Ophthalmopathy"
] | [
"University of Toronto"
] | [
"Allergan UC"
] | [
[
{
"name": "A型肉毒毒素",
"lang": "CN"
},
{
"name": "Onabotulinumtoxin A",
"lang": "EN"
},
{
"name": "A 型ボツリヌス毒素",
"lang": "JP"
}
]
] | null |
NCT05303636 | [
{
"id_field": "org_study_id",
"id_value": [
"LF111/401"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2020-000412-30"
]
}
] | https://clinicaltrials.gov/study/NCT05303636 | LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women | The primary objective of this study is to evaluate the impact of LF111 and drospirenone (DRSP) 3.5 mg chewable tablets on bone mineral density (BMD) at the lumbar spine after 12 months (13 medication cycles) of investigation in comparison to non-hormonal contraceptive methods. Secondary objectives include further evalu... | A Multicenter, Open-label, Controlled Study to Investigate the Effect of Either LF111 or Drospirenone Chewable Tablets on Bone Mineral Density (BMD) in Adolescent and Adult Women in Comparison With Non-users of Hormonal Contraceptive Methods | [
{
"description": "Drospirenone 4 mg tablet (LF1111) orally daily on days 1-24, followed by placebo tablet orally daily on days 25-28 (available in USA and Europe) or drospirenone 3.5 mg chewable tablet chewed daily on days 1-24, followed by placebo tablet chewed daily on days 25-28) (available in USA only).",
... | [
{
"design_group_description": "Subjects in the USA who choose to use the hormonal contraceptive method may choose between LF111 tablets or drospirenone (DRSP) 3.5 mg chewable tablets. 1/3 of subjects in the USA should receive DRSP 3.5 mg chewable tablets. The DRSP 3.5 mg chewable tablets are not available to su... | [
"Change in Bone Mineral Density",
"Bone Loss"
] | [
"Insud Pharma SL"
] | [
"Chemo Research SL"
] | [
[
{
"name": "屈螺酮",
"lang": "CN"
},
{
"name": "Drospirenone",
"lang": "EN"
},
{
"name": "ドロスピレノン",
"lang": "JP"
}
]
] | null |
NCT01466712 | [
{
"id_field": "org_study_id",
"id_value": [
"S53020"
]
}
] | https://clinicaltrials.gov/study/NCT01466712 | Evaluate the Effects of Formoterol and Beclomethasone Dipropionate Combination Therapy on Small Airways Function | Inuvair® is a novel fixed combination product used in the treatment of asthma and under clinical development for the treatment of COPD. Thanks to the extrafine particle size, it is able to target the whole bronchial tree, including the small airways and hence, is expected to act in these airways and it may thus be bene... | Randomized Double-blind Placebo-controlled Crossover Study to Evaluate the Effects of Formoterol and Beclomethasone Dipropionate Combination Therapy on Small Airways Function in COPD Patients. | [
{
"description": "Tiotropium 18 µg/dose once daily (handihaler device) + formoterol, fumarate 6µg + beclometasone, dipropionate 100µg / dose (Pressurised inhaler): 2 puffs bid, for one month.",
"name": "Tiotropium + formoterol/beclometasone",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"o... | [
{
"design_group_description": "run-in of 4 weeks with thiotropium cross-over after first treatment period of 4 weeks",
"design_group_title": "Tiotropium+formoterol/beclomethasone",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"interv... | [
"COPD",
"Emphysema",
"Small Airway Disease"
] | [
"Katholieke Universiteit Leuven"
] | [
"CHIESI Farmaceutici SpA"
] | [
[
{
"name": "噻托溴铵",
"lang": "CN"
},
{
"name": "Tiotropium Bromide",
"lang": "EN"
},
{
"name": "チオトロピウム臭化物水和物",
"lang": "JP"
}
],
[
{
"name": "二丙酸倍氯米松/富马酸福莫特罗",
"lang": "CN"
},
{
"name": "Beclometasone Dipropionate/Formoter... | null |
NCT00417482 | [
{
"id_field": "org_study_id",
"id_value": [
"#5598R"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"5R01AG021488"
]
},
{
"id_field": "acronym",
"id_value": [
"ADAD"
]
}
] | https://clinicaltrials.gov/study/NCT00417482 | Antipsychotic Discontinuation in Alzheimer's Disease | In patients with Alzheimer's disease (AD) who respond to antipsychotic treatment of psychosis and/or agitation/aggression, the relapse risk after discontinuation is not established. AD patients with psychosis and/or agitation/aggression receive 16 weeks of open risperidone treatment (Phase A). Responders are then rando... | Antipsychotic Discontinuation in Alzheimer's Disease | [
{
"description": "Risperidone open label flexible dose 0.25 to 3 mg daily for first 16 weeks; dose at 16 weeks then fixed for randomized trial",
"name": "risperidone",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Risperdal"
],
"type": "Drug"
}
] | [
{
"design_group_description": "Risperidone for 16 weeks followed by risperidone for 16 weeks",
"design_group_title": "Risperidone-risperidone",
"design_group_type": "Other",
"intervention": [
{
"intervention_description": "Risperidone open label flexible dose 0.25 to 3 mg daily for fir... | [
"Alzheimer Disease",
"Psychotic Disorders",
"Agitation",
"Aggression"
] | [
"The New York State Psychiatric Institute"
] | [
"Columbia University",
"National Institute on Aging"
] | [
[
{
"name": "利培酮",
"lang": "CN"
},
{
"name": "Risperidone",
"lang": "EN"
},
{
"name": "リスペリドン",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "ADAD"
}
] |
NCT01541475 | [
{
"id_field": "org_study_id",
"id_value": [
"112063"
]
},
{
"id_field": "secondary_id",
"id_value": [
"GSK IIT"
]
}
] | https://clinicaltrials.gov/study/NCT01541475 | Neuroimaging Study of Bupropion Treatment in Patients With Major Depressive Disorder | The current study is being conducted in patients with major depression. The study aims to 1) investigate the combined effects of selective serotonin reuptake inhibitor (SSRI) and bupropion compared to SSRI alone on the improvements of depressive symptoms, fatigue, hypersomnia, and neurocognitive functions, 2) observe s... | Neuroimaging Study of Bupropion Treatment in Patients With Major Depressive Disorder | [
{
"description": "Week 0-1: Escitalopram 10mg, Bupropion 150mg Week 2-3: Escitalopram 10mg, Bupropion 300mg Week 4-8: Escitalopram 20mg, Bupropion 300mg",
"name": "Bupropion, Escitalopram",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Week 0-3: E... | [
{
"design_group_title": "Escitalopram + Bupropion",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Week 0-1: Escitalopram 10mg, Bupropion 150mg Week 2-3: Escitalopram 10mg, Bup... | [
"Major Depressive Disorder"
] | [
"Ewha Womans University"
] | [
"GSK Plc"
] | [
[
{
"name": "盐酸安非他酮",
"lang": "CN"
},
{
"name": "Bupropion Hydrochloride",
"lang": "EN"
}
],
[
{
"name": "草酸艾司西酞普兰",
"lang": "CN"
},
{
"name": "Escitalopram Oxalate",
"lang": "EN"
},
{
"name": "エスシタロプラムシュウ酸塩",
"lang"... | null |
NCT01131806 | [
{
"id_field": "org_study_id",
"id_value": [
"VGHIRB No. 98-10-16"
]
},
{
"id_domain": "Veterans General Hospital-TAIPEI",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"CM981016"
]
}
] | https://clinicaltrials.gov/study/NCT01131806 | Comparing Treatment Efficacy With HD/MD Flu Plus Sal in Chronic Obstructive Pulmonary Disease (COPD) Patients | Chronic obstructive pulmonary disease is characterized as inflammatory airway with not fully reversible airflow limitation.Combination treatment with inhaled corticosteroid (ICS) and long-acting β2 agonists (LABA)attains an improved control of symptoms and lung function, that are superior to those associated with eithe... | Comparing Treatment Efficacy With High and Medium Dose of Fluticasone in Combination With Salmeterol in COPD Patients | [
{
"description": "fluticasone 125mcg/salmeterol 25mcg 2puffs/day x 52 weeks",
"name": "fluticasone/ salmeterol 125/25 mcg/puff",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Seretide evohaler 125(GlaxoSmithKline)"
],
"type": "Drug"
},
{
"description":... | [
{
"design_group_description": "fluticasone125 mcg/ salmeterol 25 mcg 2puffs (medium dose group) inhaled twice daily; salbutamol evohaler allowed from 100 to 400 mcg for inhalation as needed basis.",
"design_group_title": "MD Flu/Sal",
"design_group_type": "Active Comparator",
"design_group_type_norm... | [
"Chronic Obstructive Pulmonary Disease"
] | [
"Taipei Veterans General Hospital"
] | [
"National Taiwan University Hospital",
"Far-Eastern Memorial Hospital"
] | [
[
{
"name": "丙酸氟替卡松/昔萘酸沙美特罗",
"lang": "CN"
},
{
"name": "Fluticasone propionate/Salmeterol xinafoate",
"lang": "EN"
},
{
"name": "サルメテロールキシナホ酸塩/フルチカゾンプロピオン酸エステル",
"lang": "JP"
}
]
] | null |
NCT02996409 | [
{
"id_field": "org_study_id",
"id_value": [
"51623"
]
},
{
"id_field": "acronym",
"id_value": [
"HAT"
]
}
] | https://clinicaltrials.gov/study/NCT02996409 | High-Volume Image-Guided Injection in Chronic Midportion Achilles Tendinopathy | Overuse injury of the Achilles tendon is a common entity in athletes. Currently, the usual treatment for chronic midportion Achilles tendinopathy is an eccentric exercise program. In most cases this gives satisfactory results, however there is a significant group of patients in which the exercise program is not suffici... | The Value of a High-Volume Image-Guided Injection in Chronic Midportion Achilles Tendinopathy: a Double-blind, Randomized, Placebo-controlled Clinical Trial | [
{
"description": "High Volume Image-Guided Injection with a saline/lidocain solution",
"name": "HVIGI",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Lidocain 1.0% 10 ml",
"Saline 0.9% 40 ml"
],
"type": "Drug"
},
{
"description": "Placebo control... | [
{
"design_group_description": "HVIGI: Injection of 50 cc ( 40 cc 0,9% sodium chloride solution + 10 cc 1% lidocain) in combination with a progressive exercise program and gradual return to sports activities.",
"design_group_title": "High-Volume Image-Guided Injection",
"design_group_type": "Experimental... | [
"Tendinopathy",
"Achilles Tendon Pain",
"Injection Site Fibrosis"
] | [
"Erasmus Universitair Medisch Centrum Rotterdam"
] | [
"Dutch Arthritis Association"
] | [
[
{
"name": "盐酸利多卡因",
"lang": "CN"
},
{
"name": "Lidocaine Hydrochloride",
"lang": "EN"
},
{
"name": "リドカイン塩酸塩",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "HAT"
}
] |
NCT01147510 | [
{
"id_field": "org_study_id",
"id_value": [
"AJIRB-GEN-CT4-10-095"
]
},
{
"id_domain": "The Korean Health 21 R&D Project and MSD",
"id_field": "secondary_id",
"id_type": "Other Grant/Funding Number",
"id_value": [
"A070001"
]
},
{
"id_field": "acronym",
"i... | https://clinicaltrials.gov/study/NCT01147510 | Asthma Control in Elderly Patients With Montelukast | To compare the efficacy of combination therapy of montelukast plus low dose inhaled budesonide and single therapy of medium dose inhaled budesonide on asthma control such as inflammatory markers and clinical indicators and to compare treatment response according to leukotriene related genotypes in elderly patients with... | A Randomized Controlled Study of Montelukast Plus Low Dose Inhaled Budesonide Versus Medium Dose Inhaled Budesonide on Asthma Control in Elderly Patients | [
{
"description": "Two puffs of Pulmicort ® turbuhaler 200µg/puff between 7 a.m. and 10 a.m and take orally a tablet of Singulair® 10mg one time per day.",
"name": "Combination of low ICS and montelukast",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description... | [
{
"design_group_title": "Monotherapy of medium dose ICS",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"intervention_description": "Two puffs of Pulmicort ® turbuhaler 200µg/puff between 7 a.m. and ... | [
"Persistent Asthma",
"Elderly"
] | [
"Ajou University"
] | [
"Hallym University Medical Center",
"Korea University Guro Hospital",
"MCM Vaccines B.V."
] | [
[
{
"name": "布地奈德",
"lang": "CN"
},
{
"name": "Budesonide",
"lang": "EN"
},
{
"name": "ブデソニド",
"lang": "JP"
}
],
[
{
"name": "孟鲁司特钠",
"lang": "CN"
},
{
"name": "Montelukast sodium",
"lang": "EN"
},
{
"n... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "ACEM"
}
] |
NCT05288374 | [
{
"id_field": "org_study_id",
"id_value": [
"Celecoxib in radius fracture"
]
}
] | https://clinicaltrials.gov/study/NCT05288374 | Celecoxib in Postoperative Analgesia for Radius Fracture Surgery | Patients scheduled for elective osteosynthesis of the distal radius will be randomized to receive celecoxib 100 mg orally (PO) at 6 in the morning before surgery and every 12 hours for 2 days thereafter, or a placebo pill in the same regimen. After surgery under general anaesthesia, they will receive paracetamol 1 g in... | Celecoxib for Treatment of Postoperative Pain After Osteosynthesis of Distal Radius Fracture | [
{
"description": "Administering Celecoxib 100 mg (Celebrex) regularly every 12 hours for 3 days starting at 6 in the morning on the day of surgery",
"name": "Celecoxib 100 mg",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Celebrex 100 mg"
],
"type": "Drug"
... | [
{
"design_group_description": "Celecoxib 100 mg orally will be administered in the day of surgery at 6 in the morning and will be continued regularly at 6 in the morning and 6 in the afternoon for 3 days.",
"design_group_title": "Celecoxib",
"design_group_type": "Experimental",
"design_group_type_no... | [
"Pain, Postoperative"
] | [
"University of Charles"
] | [
"University Hospital Královské Vinohrady"
] | [
[
{
"name": "塞来昔布",
"lang": "CN"
},
{
"name": "Celecoxib",
"lang": "EN"
},
{
"name": "セレコキシブ",
"lang": "JP"
}
]
] | null |
NCT03467763 | [
{
"id_field": "org_study_id",
"id_value": [
"1706018342"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. AHRQ Grant/Contract",
"id_value": [
"K08HS023898"
]
},
{
"id_field": "acronym",
"id_value": [
"TreatMet"
]
}
] | https://clinicaltrials.gov/study/NCT03467763 | Trial of an Intervention to Improve Metformin Persistence and Adherence | Metformin is a safe and effective first-line drug for type 2 diabetes that is also widely recommended for weight loss and diabetes prevention. But, metformin is associated with gastrointestinal and other side effects which prevent its use in 10-20% of patients and appear to limit the usable dose in others. This study i... | Trial of an Intervention to Improve Metformin Persistence and Adherence | [
{
"description": "Metformin hydrochloride extended release tablets in dosages of 250 mg, 500 mg, 750 mg, and 1,000 mg. Individual encapsulations of metformin will contain dosages of 250 mg or 500 mg.",
"name": "Metformin Extended Release Oral Tablet",
"normalized_type": "3d1aa88261d64c038413723970f2b58b... | [
{
"design_group_description": "Patients will be assigned to take their baseline medication regimen plus 2 weeks of 250 mg per day of metformin extended release, followed by 500 mg metformin XR, 750 mg, and 1,000 mg metformin XR with each treatment period separated by a 2-week course of placebo.",
"design_gr... | [
"Metformin Adverse Reaction",
"Tolerance"
] | [
"Weill Medical College of Cornell University"
] | [
"Agency for Healthcare Research & Quality"
] | [
[
{
"name": "盐酸二甲双胍",
"lang": "CN"
},
{
"name": "Metformin Hydrochloride",
"lang": "EN"
},
{
"name": "メトホルミン塩酸塩",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "a28308ee352288224942e285e2e94d94",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "TreatMet"
}
] |
NCT00140465 | [
{
"id_field": "org_study_id",
"id_value": [
"GE IDE No. A00803"
]
}
] | https://clinicaltrials.gov/study/NCT00140465 | 75 or 150 mg Clopidogrel Maintenance Doses Following PCI (ISAR-CHOICE-2) | The purpose of the study is to test whether an increase of the maintenance dose of clopidogrel from 75 to 150 mg per day results in an additional suppression of ADP-induced platelet aggregation | A Double-Blind, Randomized Comparison Between Two Different Clopidogrel Maintenance Doses After Percutaneous Coronary Intervention (ISAR-CHOICE-2) | [
{
"description": "after PCI",
"name": "Clopidogrel",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Iscover",
"Plavix"
],
"type": "Drug"
},
{
"description": "after PCI",
"name": "Clopidogrel",
"normalized_type": "3d1aa88261d64c038413723970... | [
{
"design_group_description": "75 mg Clopidogrel Maintenance Doses",
"design_group_title": "1",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"intervention_description": "after PCI",
"int... | [
"Coronary Disease"
] | [
"Deutsches Herzzentrum Berlin"
] | [
"Technische Universität München"
] | [
[
{
"name": "硫酸氢氯吡格雷",
"lang": "CN"
},
{
"name": "Clopidogrel Bisulfate",
"lang": "EN"
},
{
"name": "クロピドグレル硫酸塩",
"lang": "JP"
}
]
] | null |
NCT01818661 | [
{
"id_field": "org_study_id",
"id_value": [
"12-008988, 17-010087"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"R01DC012519-09"
]
}
] | https://clinicaltrials.gov/study/NCT01818661 | Longitudinal Multi-Modality Imaging in Progressive Apraxia of Speech | The study is designed to determine the relationship between structural and functional changes in the brain on imaging and progression of speech and language, neurological and neuropsychological features in patients with neurodegenerative apraxia of speech (AOS). | Longitudinal Multi-Modality Imaging in Progressive Apraxia of Speech | [
{
"description": "This is used to assess Tau burden in the brain.",
"name": "AV-1451",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "All subjects will receive Tau PET scan on approximately day 1 or day 2 of study to assess Tau burden in the brain.",
"design_group_title": "Tau positron emission tomography (PET)",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354... | [
"PPA",
"Non-fluent Aphasia",
"Apraxia of Speech",
"Primary Progressive Non-fluent Aphasia",
"Primary Progressive Aphasia"
] | [
"Mayo Clinic"
] | [
"National Institute on Deafness & Other Communication Disorder"
] | [
[
{
"name": "氟妥西吡",
"lang": "CN"
},
{
"name": "Flortaucipir F-18",
"lang": "EN"
},
{
"name": "フロルタウシピル（１８Ｆ）",
"lang": "JP"
}
]
] | null |
NCT01740947 | [
{
"id_field": "org_study_id",
"id_value": [
"2011-002211-28"
]
},
{
"id_field": "acronym",
"id_value": [
"SELECT"
]
}
] | https://clinicaltrials.gov/study/NCT01740947 | Does Administration of Antibiotics in Patients Undergoing Surgery for Colorectal Cancer Result in Less Complications and Better Prognosis? | The primary objectives of this randomized clinical trial are to evaluate if perioperative SDD can reduce clinical anastomotic leakage rate and its septic consequences as well as other infectious complications. By reduction of septic complications long-term oncological outcome might simultaneously improve. | Perioperative Selective Decontamination of the Digestive Tract (SDD) in Elective Colorectal Cancer Patients: a Multicenter Randomized Clinical Trial | [
{
"description": "SDD suspension contains per dose of 10 ml 100 mg colistin sulfate, 80 mg tobramycin and 500 mg amphotericin B",
"name": "Selective decontamination of the digestive tract (SDD) (colistin sulfate, tobramycin, amphotericin B)",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"o... | [
{
"design_group_description": "Standard treatment for colorectal cancer",
"design_group_title": "Standard treatment",
"design_group_type": "No Intervention"
},
{
"design_group_description": "Standard treatment + SDD perioperatively 4 times daily 10 ml of SDD suspension, consisting of 100mg colis... | [
"Colorectal Cancer"
] | [
"Stichting Onderzoek Cancer Center Amsterdam"
] | [
"Dutch Digestive Diseases Foundation"
] | [
[
{
"name": "妥布霉素",
"lang": "CN"
},
{
"name": "Tobramycin",
"lang": "EN"
},
{
"name": "トブラマイシン",
"lang": "JP"
}
],
[
{
"name": "硫酸多粘菌素E",
"lang": "CN"
},
{
"name": "Colistin Sulfate",
"lang": "EN"
}
],
[
... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "SELECT"
}
] |
NCT02280239 | [
{
"id_field": "org_study_id",
"id_value": [
"H13-01160"
]
},
{
"id_field": "acronym",
"id_value": [
"SEA-ICU"
]
}
] | https://clinicaltrials.gov/study/NCT02280239 | Safety and Efficacy of Acetaminophen in the Intensive Care Unit. | The intensive care unit (ICU) team needs to know what effects acetaminophen has in critically ill patients. Acetaminophen is better known as Tylenol. It is the drug given to reduce fever. Most research that has looked at how safe and effective this drug is, has been done with healthy people. Those studies tell us it is... | Safety and Antipyretic Efficacy of Acetaminophen in the Febrile Intensive Care Unit Patient. | [
{
"description": "one-time dose of acetaminophen 650mg given via the enteral route (via the gut)",
"name": "Acetaminophen",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Tylenol"
],
"type": "Drug"
},
{
"description": "one-time dose of placebo (identica... | [
{
"design_group_description": "This group consists of stable but febrile ICU patients (temp >38.3°C). Participants in this group will receive a one-time dose of placebo via the enteral route (via the gut), after which vital signs (including continuous measures of core temperature, heart rate, and blood pressure... | [
"Critical Illness",
"Fever"
] | [
"University of British Columbia"
] | [
"Vancouver Coastal Health Research Institute"
] | [
[
{
"name": "对乙酰氨基酚",
"lang": "CN"
},
{
"name": "Acetaminophen",
"lang": "EN"
},
{
"name": "アセトアミノフェン",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "e208205d2285a2a43a2294e8a424349a",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "SEA-ICU"
}
] |
NCT05372315 | [
{
"id_field": "org_study_id",
"id_value": [
"SPENCER-2022-401"
]
},
{
"id_field": "acronym",
"id_value": [
"DEXTENZA"
]
}
] | https://clinicaltrials.gov/study/NCT05372315 | Efficacy of Dextenza Insert in Upper vs Lower Punctum Following Cataract Surgery With PCIOL. | To assess the safety and effectiveness of treatment with an intracanalicular dexamethasone (0.4mg) insert in the operating room following cataract surgery/intraocular lens implant (IOL) with or without iStent/Hydrus/Goniotomy when placed in the lower punctum compared to the upper punctum. | A Randomized, Controlled Study to Evaluate the Safety and Effectiveness of Treatment With an Intracanalicular Dexamethasone (0.4mg) Ophthalmic Insert in the Operating Room Following Cataract Surgery/Intraocular Lens Implant (IOL). | [
{
"description": "(dexamethasone ophthalmic insert)-for the treatment of ocular inflammation and pain following following ophthalmic surgery.",
"name": "Dextenza 0.4Mg Ophthalmic Insert",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "DEXTENZA (dexamethasone ophthalmic insert, 0.4mg) for intracanalicular use<br/>Group 1 (up to 40 eyes) will receive the insert in the lower punctum on the day of surgery in the OR.",
"design_group_title": "Lower Punctum Insertion (Group 1)",
"design_group_type": "Other",
... | [
"Cataract"
] | [
"Iworks Laser & Vision Center"
] | [
"Ocular Therapeutix, Inc."
] | [
[
{
"name": "地塞米松",
"lang": "CN"
},
{
"name": "Dexamethasone",
"lang": "EN"
},
{
"name": "デキサメタゾン",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "a5de59de225a48e5490224e558e20a34",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "DEXTENZA"
}
] |
NCT01024647 | [
{
"id_field": "org_study_id",
"id_value": [
"CMZ-2010"
]
}
] | https://clinicaltrials.gov/study/NCT01024647 | Optimizing Cimzia in Crohn's Patients | The purpose of this study is to determine if increasing the dose and/or dosing frequency of certolizumab pegol (Cimzia) is effective in regaining and optimizing response in patients with moderate to severe Crohn's disease. | Optimizing Response in Crohn's Disease Patients Who Have Insufficient Initial Response or Who Have Loss of Successful Response to Certolizumab Pegol (Cimzia) Induction Therapy | [
{
"description": "certolizumab pegol 200 mg every 2 weeks",
"name": "certolizumab pegol",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"other_name": [
"Cimzia"
],
"type": "Biological"
},
{
"description": "certolizumab pegol 400 mg every 2 weeks",
"name": "certoliz... | [
{
"design_group_description": "Loss of Response Reinduction Responders:certolizumab pegol (Cimzia) 200 mg every 2 weeks",
"design_group_title": "Loss of Reponse Reinduction Responders",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
... | [
"Crohn's Disease"
] | [
"Atlanta Gastroenterology Associates LLC"
] | [
"UCB Pharma GmbH"
] | [
[
{
"name": "培塞利珠单抗",
"lang": "CN"
},
{
"name": "Certolizumab Pegol",
"lang": "EN"
},
{
"name": "セルトリズマブ ペゴル（遺伝子組換え）",
"lang": "JP"
}
]
] | null |
NCT05697211 | [
{
"id_field": "org_study_id",
"id_value": [
"ORION-HF"
]
}
] | https://clinicaltrials.gov/study/NCT05697211 | ORal IrON Supplementation with Ferric Maltol in Treating Iron Deficiency and Anaemia in Patients with Heart Failure (ORION-HF) | This is an open-label, single arm, multicenter pilot-study to explore the safety, tolerability and efficacy of oral iron supplementation with ferric maltol in treating iron deficiency and anaemia in patients with heart failure. | A Pilot Study to Explore Safety, Tolerability and Efficacy of ORal IrON Supplementation with Ferric Maltol in Treating Iron Deficiency and Anaemia in Patients with Heart Failure | [
{
"description": "In this trial Feraccru® 30 mg hard capsules will be used. Each capsule contains 30 mg iron (as ferric maltol), 91.5 mg of lactose, 0.5 mg of Allura Red AC (E129) and 0.3 mg Sunset Yellow FCF (E110) as excipients with known effects.",
"name": "Ferric maltol 30 mg (Feraccru®)",
"normaliz... | [
{
"design_group_description": "Treatment with Feraccru® 30 mg hard capsules (Ferric maltol 30 mg). One capsule twice daily p.o., morning and evening, on an empty stomach",
"design_group_title": "Feraccru® 30 mg hard capsules",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "... | [
"Heart Failure, Left-sided",
"Anemia, Iron Deficiency"
] | [
"Hannover Medical School"
] | [
"Norgine Ltd."
] | [
[
{
"name": "麦芽酚铁",
"lang": "CN"
},
{
"name": "Ferric Maltol",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "ORION-HF"
}
] |
NCT06710184 | [
{
"id_field": "org_study_id",
"id_value": [
"DAN-FOXY"
]
},
{
"id_field": "secondary_id",
"id_type": "EU Trial (CTIS) Number",
"id_value": [
"2024-517229-18-00"
]
},
{
"id_field": "acronym",
"id_value": [
"FOXY"
]
}
] | https://clinicaltrials.gov/study/NCT06710184 | Treatment With Aspirin Alone Versus Aspirin in Combination With Fondaparinux Before Early Coronary Assessment in Patients With Non-ST-Elevation Myocardial Infarction | The main goal of this study is to compare two treatments in patients with a specific type of heart attack called Non-ST-elevation Myocardial Infarction (NSTEMI). The investigators want to find out whether using aspirin alone is as effective and safer than using aspirin together with a second blood thinner called fondap... | Aspirin Versus Aspirin and Fondaparinux Prior to Early Invasive Strategy in Patients With NSTEMI | [
{
"description": "Aspirin bolus of 300 mg followed by 75 mg daily until CAG",
"name": "Aspirin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Fondaprinux 2.5 mg subcutaneus daily until CAG (1.5 mg for patients with eGFR 20-50 ml/min/1.73m2)",
... | [
{
"design_group_description": "Treatment with aspirin alone. The intervention is removal of treatment with fondaparinux",
"design_group_title": "Aspirin alone",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
... | [
"NSTEMI - Non-ST Segment Elevation Myocardial Infarction (MI)",
"Acute Myocardial Infarction (AMI)"
] | [
"University of Aarhus"
] | [
"Aalborg University Hospital",
"Odense University Hospital",
"Randers Regional Hospital",
"Horsens Regional Hospital",
"Rigshospitalet",
"Danske Regioner"
] | [
[
{
"name": "阿司匹林",
"lang": "CN"
},
{
"name": "Aspirin",
"lang": "EN"
},
{
"name": "サリチル酸",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "22d885e880e2e325ade8e5e298aae4ee",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "FOXY"
}
] |
NCT02473809 | [
{
"id_field": "org_study_id",
"id_value": [
"07052015"
]
},
{
"id_field": "acronym",
"id_value": [
"LIRABONE"
]
}
] | https://clinicaltrials.gov/study/NCT02473809 | The Effect of Liraglutide on Bone Turnover, Bone Mass and Bone Cell Function | The purpose of this study is to test whether liraglutide, a drug approved and widely used in the treatment of type 2 diabetes, has an effect on bone mass and bone cell function. Type 2 diabetes may cause multiple complications, and it is well known that patients with type 2 diabetes have a higher risk of fractures. If ... | The Effect of Liraglutide on Bone Turnover, Bone Mass and Bone Cell Function | [
{
"description": "Once daily",
"name": "Liraglutide",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Victoza"
],
"type": "Drug"
},
{
"description": "Once daily",
"name": "Placebo",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"othe... | [
{
"design_group_description": "Liraglutide (\"Victoza\"), subcutaneous 1,8 mg once daily for 180 days",
"design_group_title": "Liraglutide",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention... | [
"Diabetes Complications",
"Osteoporosis"
] | [
"University of Aarhus"
] | [
"Århus Universitetshospital",
"Novo Nordisk A/S"
] | [
[
{
"name": "利拉鲁肽",
"lang": "CN"
},
{
"name": "Liraglutide",
"lang": "EN"
},
{
"name": "リラグルチド（遺伝子組換え）",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "LIRABONE"
}
] |
NCT00197639 | [
{
"id_field": "org_study_id",
"id_value": [
"HSC 10913"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"R01HD042964"
]
}
] | https://clinicaltrials.gov/study/NCT00197639 | Pharmacokinetic Study of Indinavir Drug Levels When Boosted With Ritonavir in Thailand | This study looks at the ways indinavir drug levels, when boosted with ritonavir, may vary from patient to patient. The study population are HIV+ Thai individuals. | A Pharmacokinetic Study to Assess the Inter-patient Variability of Indinavir Drug Levels When Boosted With Ritonavir in Thai Patients on Highly Active Antiretroviral Therapy | [
{
"name": "Ritonavir-boosted indinavir",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "multiple_drugs",
"type": "Drug"
}
] | null | [
"HIV Infection"
] | [
"Harvard T.H. Chan School of Public Health"
] | [
"National Institute of Child Health & Human Development"
] | [
[
{
"name": "利托那韦",
"lang": "CN"
},
{
"name": "Ritonavir",
"lang": "EN"
},
{
"name": "リトナビル",
"lang": "JP"
}
],
[
{
"name": "硫酸茚地那韦",
"lang": "CN"
},
{
"name": "Indinavir Sulfate",
"lang": "EN"
}
]
] | null |
NCT01560052 | [
{
"id_field": "org_study_id",
"id_value": [
"GI-R-01-2011"
]
},
{
"id_field": "acronym",
"id_value": [
"TESTING"
]
}
] | https://clinicaltrials.gov/study/NCT01560052 | Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study) | This study will evaluate the long-term efficacy and safety of low dose oral methylprednisolone compared to matching placebo, on a background of routine RAS inhibitor therapy, in preventing kidney events in patients with IgA nephropathy and features suggesting a high risk of progression. | Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study Low Dose Study | [
{
"description": "Original Cohort:<br/>Oral methylprednisolone or placebo 0.8mg/kg/day with a maximum of 48mg/day x 2months, taper by 8mg/day every month, patients will also receive optimal blood pressure control and full dose of ACE inhibitors or ARBs as recommended by guidelines<br/>Low Dose Cohort:<br/>Oral ... | [
{
"design_group_description": "oral methylprednisolone<br/>Original Cohort:<br/>Methylprednisolone group; start at 0.8mg/kg/day with a maximal 48mg/kg/day x 2months, taper by 8mg/day every month with optimal blood pressure control and full dose of ACE inhibitors or ARBs as recommended by guidelines.<br/>Low Dos... | [
"IgA Glomerulonephritis"
] | [
"The George Institute for Global Health"
] | [
"Peking University First Hospital"
] | [
[
{
"name": "甲泼尼龙",
"lang": "CN"
},
{
"name": "Methylprednisolone",
"lang": "EN"
},
{
"name": "メチルプレドニゾロン",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "5e892e5e4d89e5985829eaad4e8a5820",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code": "8ed22d022ae50e2809e8eede208e54e5",
"s... |
NCT06002906 | [
{
"id_field": "org_study_id",
"id_value": [
"20-5008"
]
}
] | https://clinicaltrials.gov/study/NCT06002906 | The Use of Indocyanine Green to Visualize Blood Flow to the Gastrojejunostomy During Bariatric Surgery. | This is an interventional pilot study aimed to evaluate the use of NIF imaging as an intraoperative aid to assess the anastomotic blood flow to the gastric pouch and gastrojejunostomy during Roux-en-Y gastric bypass surgery and to determine its long-term impact on the rate of marginal ulceration, leaks and stricture. | The Use of Indocyanine Green to Visualize Blood Flow to the Gastrojejunostomy During Bariatric Surgery | [
{
"description": "Indocyanine green (ICG) is a safe, sterile, water-soluble molecule that binds to plasma proteins and can be injected intravenously. ICG will be injected intravenously based on the patient's weight prior to and after making the GJ anastomosis and a 10 mL bolus of normal saline will be immediate... | [
{
"design_group_description": "The interventional group will receive indocyanine green during bariatric surgery inside the operating room before and after making the gastrojejunostomy.",
"design_group_title": "Interventional group (with drug)",
"design_group_type": "Experimental",
"design_group_type... | [
"Ulcer, Gastric",
"Obesity, Morbid"
] | [
"University Health Network"
] | [
"Stryker Endoscopy"
] | [
[
{
"name": "吲哚菁绿",
"lang": "CN"
},
{
"name": "Indocyanine Green",
"lang": "EN"
},
{
"name": "インドシアニングリーン",
"lang": "JP"
}
]
] | null |
NCT06474299 | [
{
"id_field": "org_study_id",
"id_value": [
"2024-0019"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"R01CA290895"
]
},
{
"id_domain": "UW Madison",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"i... | https://clinicaltrials.gov/study/NCT06474299 | The Avenues Study: Dual Use Cessation | The overarching goal of this research is to determine the most effective approach for helping dual users of cigarettes and electronic nicotine delivery systems (ENDS) quit smoking. 500 participants will be enrolled and can expect to be on study for 12 months. | Dual Use Cessation: A MOST Screening Trial to Identify Effective Interventions to Help People Who Smoke and Vape | [
{
"description": "0.5 mg pill once a day for the first 3 days and then increase to a 0.5 mg pill twice a day (at least 8 hours apart) for 4 days prior to the TQD. On the 8th day (the TQD), participants will increase to their target maintenance dose of a 1 mg pill twice daily",
"name": "Varenicline",
"no... | [
{
"design_group_title": "Varenicline, Dual Focused, 1 session",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"intervention_description": "Dual Focused Cessation Counseling will focus on quitting bot... | [
"Smoking Cessation",
"Electronic Cigarette Use"
] | [
"University of Wisconsin-Madison"
] | [
"National Cancer Institute"
] | [
[
{
"name": "尼古丁",
"lang": "CN"
},
{
"name": "Nicotine",
"lang": "EN"
}
],
[
{
"name": "酒石酸伐尼克兰",
"lang": "CN"
},
{
"name": "Varenicline Tartrate",
"lang": "EN"
},
{
"name": "バレニクリン酒石酸塩",
"lang": "JP"
}
]
] | null |
NCT01974817 | [
{
"id_field": "org_study_id",
"id_value": [
"WI170883"
]
}
] | https://clinicaltrials.gov/study/NCT01974817 | Study Response of 13-valent Conjugate Pneumococcal Vaccine in Patients With End Stage Renal Disease | The purpose of the study is to determine the response of 13-valent conjugate pneumococcal vaccine in patients 50 years or older with end stage renal disease on dialysis.<br/>The study will also try to determine Streptococcus pneumoniae colonization in patients 50 years or older with end stage renal disease on dialysis. | Streptococcus Pneumoniae Colonization and Immunogenicity of 13-valent Conjugate Pneumococcal Vaccine in Patients 50 Years or Older With End Stage Renal Disease on Dialysis. | [
{
"description": "0.5ml IM for one dose",
"name": "13-valent conjugate pneumococcal vaccine",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"other_name": [
"Prevnar-13"
],
"type": "Biological"
}
] | [
{
"design_group_description": "Patients will receive one dose of 0.5 ml 13-valent conjugate pneumococcal vaccine (Prevnar-13) intra-muscularly.",
"design_group_title": "Vaccine",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"interven... | [
"End Stage Renal Disease"
] | [
"Michigan State University"
] | [
"Pfizer Inc."
] | [
[
{
"name": "13价肺炎球菌多糖结合疫苗 (辉瑞制药)",
"lang": "CN"
},
{
"name": "Pneumococcal polysaccharide conjugate vaccine",
"lang": "EN"
},
{
"name": "沈降１３価肺炎球菌結合型ワクチン",
"lang": "JP"
}
]
] | null |
NCT06752850 | [
{
"id_field": "org_study_id",
"id_value": [
"Sobi.BIVV001-004"
]
},
{
"id_field": "secondary_id",
"id_type": "EU Trial (CTIS) Number",
"id_value": [
"2024-512066-33-00"
]
}
] | https://clinicaltrials.gov/study/NCT06752850 | A Study to Investigate the Course of Synovial Hypertrophy in Patients With Haemophilia A on Efanesoctocog Alfa Prophylaxis | The rationale for conducting this open-label phase 4 study is to assess whether once-weekly prophylaxis with efanesoctocog alfa (50 IU/kg) improves the disease course of existing synovial hypertrophy and prevents the risk of joint bleeds in patients with moderate or severe haemophilia A. The use of imaging assessments ... | A 12-month, Interventional, Open-label, Phase 4 Study in Europe (SHINE) to Investigate the Course of Synovial Hypertrophy as Detected by Joint Ultrasound and MRI in Patients With Haemophilia A on Efanesoctocog Alfa Prophylaxis. | [
{
"description": "50 IU/kg once weekly, Intravenous injection",
"name": "Efanesoctocog alfa",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_title": "Study Treatment Group",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "50 IU/kg once weekly, Intravenous injection",
"intervention_name": "Efan... | [
"Haemophilia A (Moderate or Severe)",
"Hemophilia, Classic",
"Haemophilia",
"Hemophilia",
"Classic Hemophilia",
"Synovial Hypertrophy"
] | [
"Swedish Orphan Biovitrum AB"
] | [
"PSI CRO AG"
] | [
[
{
"name": "Efanesoctocog alfa",
"lang": "EN"
},
{
"name": "エフアネソクトコグ アルファ（遺伝子組換え）",
"lang": "JP"
}
]
] | null |
NCT05213156 | [
{
"id_field": "org_study_id",
"id_value": [
"1094/31-12-18"
]
}
] | https://clinicaltrials.gov/study/NCT05213156 | Concentration of Ofloxacin Into the Aqueous Humour of Patients With Dry Eye Disease | After topical installation of one drop of 0.3% commercially available ofloxacin (Oxatrex®) four times at intervals of 15min in catarract patients with Dry Eye Disease, aqueous humour samples will be collected intraoperatively, one hour after the last installation. Concentration of ofloxacin in aqueous humour will be me... | Concentration of Ofloxacin Into the Aqueous Humour of Patients After Topical Instillation According to the Severity of Dry Eye Disease | [
{
"description": "0.3% ofloxacin eye drops in single doses",
"name": "Oxatrex",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "Control Group",
"design_group_title": "Patients without Dry Eye Disease",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"intervention_description": "0.3% ofloxacin ... | [
"Dry Eye Disease"
] | [
"University of Patras"
] | [
"University of Patras"
] | [
[
{
"name": "氧氟沙星",
"lang": "CN"
},
{
"name": "Ofloxacin",
"lang": "EN"
},
{
"name": "オフロキサシン",
"lang": "JP"
}
]
] | null |
NCT03228823 | [
{
"id_field": "org_study_id",
"id_value": [
"NIH ID 9372611"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"R34HL138110-01"
]
},
{
"id_field": "acronym",
"id_value": [
"PAPS"
]
}
] | https://clinicaltrials.gov/study/NCT03228823 | Prospective Assessment of Premature Ventricular Contractions Suppression in Cardiomyopathy(PAPS) | Premature ventricular contractions (PVCs) coexist in patients with heart failure (HF) and LV dysfunction. Frequent PVCs have shown to induce a reversible cardiomyopathy (PVC-CM).<br/>This clinical pilot study will enroll 36 patients with frequent PVCs (burden >10%) and CM (LVEF <45%) and randomize them to either: 1) RF... | Prospective Assessment of Premature Ventricular Contractions Suppression in Cardiomyopathy(PAPS): A Pilot Study | [
{
"description": "RFA to achieve PVC suppression will be performed using standard techniques and protocols similar to those patients that do not participate in this clinical study.",
"name": "Radiofrequency ablation",
"normalized_type": "a49da0f516744e0f8a08ffdea4946e99",
"other_name": [
"Abla... | [
{
"design_group_description": "Radiofrequency ablation (RFA) will be performed after 3-month observation period. EPS and RFA will be performed using standard techniques and protocols similar to those patients that do not participate in this clinical study. In the event of polymorphic PVCs, all morphologies are ... | [
"Ventricular Premature Beats, Contractions, or Systoles",
"Cardiomyopathies"
] | [
"Hunter Holmes Mcguire Va Medical Center"
] | [
"National Heart, Lung & Blood Institute",
"The University of California, San Francisco",
"Wake Forest School of Medicine",
"Washington University School of Medicine",
"Virginia Commonwealth University",
"University of Calgary"
] | [
[
{
"name": "盐酸胺碘酮",
"lang": "CN"
},
{
"name": "Amiodarone Hydrochloride",
"lang": "EN"
},
{
"name": "アミオダロン塩酸塩",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "PAPS"
}
] |
NCT00870311 | [
{
"id_field": "org_study_id",
"id_value": [
"H12-48-95"
]
},
{
"id_field": "secondary_id",
"id_value": [
"NIMH (MH159107)"
]
}
] | https://clinicaltrials.gov/study/NCT00870311 | Investigation of Lithium on Signal Transduction, Gene Expression and Brain Myo-Inositol Levels in Manic Patients | This study investigates the effects of Lithium treatment on signal transduction pathways, gene expression and brain neurochemistry and structure in patients with Bipolar disorder. It is hypothesized that specific changes in these markers will correlate with lithium treatment responsiveness. | Investigation of Lithium on Signal Transduction, Gene Expression and Brain Myo-Inositol Levels in Manic Patients | [
{
"description": "300mg PO, three times daily with dose titrated to obtain a therapeutic plasma level of 0.8 to 1.2meq/L) over the first week of treatment. Total duration is a minimum of 3 weeks. Medication is dispensed in the form of blinded research capsules.",
"name": "Lithium Carbonate",
"normalized... | [
{
"design_group_description": "Bipolar Disorder patients",
"design_group_title": "Blinded Lithium",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "300mg PO, three times dai... | [
"Bipolar Disorder"
] | [
"Wayne State University (Michigan)"
] | [
"National Institute of Mental Health"
] | [
[
{
"name": "碳酸锂",
"lang": "CN"
},
{
"name": "Lithium carbonate",
"lang": "EN"
},
{
"name": "炭酸リチウム",
"lang": "JP"
}
]
] | null |
NCT00177216 | [
{
"id_field": "org_study_id",
"id_value": [
"R01MH024652"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"R01MH024652"
]
},
{
"id_domain": "University of Pittsburgh Institutional Review Board",
"id_field": "secondary_id"... | https://clinicaltrials.gov/study/NCT00177216 | Characteristics of Sleep Patterns in Young Adults With and Without Insomnia | This study will compare the symptoms, experiences, and laboratory sleep characteristics of young adults with and without insomnia. | Psychobiology and Treatment Response in Primary Insomnia | [
{
"description": "The benzodiazepine receptor agonist (BzRA), zolpidem was given in an initial dose of 5 mg by mouth every night, 30 minutes prior to bedtime. The dose was increased to a maximum of 10 mg after the first week if there was no improvement in overall symptoms (CGI score of 4 or >). The dose was dec... | [
{
"design_group_description": "The benzodiazepine receptor agonist (BzRA), zolpidem was given in an initial dose of 5 mg by mouth every night, 30 minutes prior to bedtime. The dose was increased to a maximum of 10 mg after the first week if there was no improvement in overall symptoms (CGI score of 4 or >). The... | [
"Sleep Disorders"
] | [
"University of Pittsburgh"
] | [
"National Institute of Mental Health"
] | [
[
{
"name": "草酸艾司西酞普兰",
"lang": "CN"
},
{
"name": "Escitalopram Oxalate",
"lang": "EN"
},
{
"name": "エスシタロプラムシュウ酸塩",
"lang": "JP"
}
],
[
{
"name": "酒石酸唑吡坦",
"lang": "CN"
},
{
"name": "Zolpidem Tartrate",
"lang": "EN"... | null |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.